08/18/00 JC903 U.S. PTO

jc875 U.S. PTO 09/641892 08/18/00

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1 53(b))

Attorney Docket No	195942US0
First Inventor or Application Identifier	Hiroshi IZUI, et al.
Title	METHOD FOR PRODUCING L-GLUTAMIC ACID BY FERMENTATION ACCOMPANIED BY PRECIPITATION

APPLICATION ELEMENTS
See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ■ Fee Transmittal Form (e.g. PTO/SB/17) (Submit an original and a duplicate for fee processing)
2. ■ Specification — Total Pages: 58
3. ■ Drawing(s) *(35 U.S.C. 113)* — Total Sheets: 7 (formals)
4. ■ Oath or Declaration — Total Pages: 4
   a. ■ Newly executed (original)
   b. □ Copy from a prior application *(37 C.F.R. §1.63(d))* *(for continuation/divisional with box 15 completed)*
      i. □ DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see *37 C.F.R. §1.63(d)(2) and 1.33(b).*
5. □ Incorporation By Reference *(usable if box 4B is checked)* The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4B, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS

6. □ Assignment Papers (cover sheet & document(s))
7. □ 37 C.F.R. §3.73(b) Statement *(when there is an assignee)* □ Power of Attorney
8. □ English Translation Document *(if applicable)*
9. □ Information Disclosure Statement (IDS)/PTO-1449 □ Copies of IDS Citations
10. □ Preliminary Amendment
11. ■ White Advance Serial No. Postcard
12. □ Small Entity Statement(s) □ Statement filed in prior application. Status still proper and desired.
13. ■ Certified Copy of Priority Document(s) (2) *(if foreign priority is claimed)*
14. ■ Other: Notice of Priority, Receipt of Microorganisms for the Purpose of Patent Procedure FERM BP-6614, BP-6615 AND BP-7207

15. If a CONTINUING APPLICATION, *check appropriate box, and supply the requisite information below:*
□ Continuation □ Divisional □ Continuation-in-part (CIP) of prior application no.:
Prior application information: Examiner: Group Art Unit:

16. Amend the specification by inserting before the first line the sentence:
□ This application is a □ Continuation □ Division □ Continuation-in-part (CIP) of application Serial No. Filed on
□ This application claims priority of provisional application Serial No. Filed

17. CORRESPONDENCE ADDRESS

22850

(703) 413-3000
FACSIMILE: (703) 413-2220

Name:	Norman F. Oblon MARVIN J. SPIVAK	Registration No.:	24,618
Signature:	REGISTRATION NUMBER 24,913	Date:	8/18/00
Name:		Registration No.:	

TITLE OF THE INVENTION

METHOD FOR PRODUCING L-GLUTAMIC ACID BY FERMENTATION ACCOMPANIED BY PRECIPITATION

BACKGROUND OF THE INVENTION

The present invention relates to a method for producing L-glutamic acid by fermentation accompanied by precipitation. L-Glutamic acid is widely used as a material of seasonings and so forth.

L-Glutamic acid is mainly produced by fermentative methods using so-called coryneform bacteria producing L-glutamic acid and belonging to the genus *Brevibacterium*, *Corynebacterium* or *Microbacterium*, or mutant strains thereof (Amino Acid Fermentation, pp.195-215, Gakkai Shuppan Center, 1986). As methods for producing L-glutamic acid by fermentation by using other bacterial strains, there are known a method using a microorganism belonging to the genus *Bacillus*, *Streptomyces*, *Penicillium* or the like (U.S. Patent No. 3,220,929), a method using a microorganism belonging to the genus *Pseudomonas*, *Arthrobacter*, *Serratia*, *Candida* or the like (U.S. Patent No. 3,563,857), a method using a microorganism belonging to the genus *Bacillus*, *Pseudomonas*, *Serratia*, *Aerobacter aerogenes* (currently referred to as *Enterobacter aerogenes*) or the like (Japanese Patent Publication (Kokoku) No. 32-9393), a method using a mutant strain of *Escherichia coli* (Japanese Patent Application Laid-open (Kokai) No. 5-244970) and so forth. In addition, the inventors of the present invention have proposed a method

for producing L-glutamic acid by using a microorganism belonging to the genus *Klebsiella, Erwinia* or *Pantoea* (Japanese Patent Application Laid-open No. 2000-106869).

Further, there have been disclosed various techniques for improving L-glutamic acid-producing ability by enhancing activities of L-glutamic acid biosynthetic enzymes through use of recombinant DNA techniques. For example, it has been reported that introduction of a gene coding for citrate synthase derived from *Escherichia coli* or *Corynebacterium glutamicum* was effective for enhancement of L-glutamic acid-producing ability in *Corynebacterium* or *Brevibacterium* bacteria (Japanese Patent Publication No. 7-121228). In addition, Japanese Patent Application Laid-open No. 61-268185 discloses a cell harboring recombinant DNA containing a glutamate dehydrogenase gene derived from *Corynebacterium* bacteria. Further, Japanese Patent Application Laid-open No. 63-214189 discloses a technique for improving L-glutamic acid-producing ability by amplifying a glutamate dehydrogenase gene, an isocitrate dehydrogenase gene, an aconitate hydratase gene and a citrate synthase gene.

Although L-glutamic acid productivity has been considerably increased by breeding of the aforementioned microorganisms or improvement of production methods, development of methods for more efficiently producing L-glutamic acid at a lower cost is required to respond to further increase of the demand in future.

There is known a method wherein fermentation is performed with crystallizing L-amino acid accumulated in

culture (Japanese Patent Application Laid-open No. 62-288). In this method, the L-amino acid concentration in the culture is maintained below a certain level by precipitating the accumulated L-amino acid in the culture. Specifically, L-tryptophan, L-tyrosine or L-leucine is precipitated during fermentation by adjusting temperature and pH of the culture or adding a surface active agent to the medium.

While a fermentative method with precipitating L-amino acid is known as described above, amino acids suitable for this method are those of relatively low water solubility, and no example of applying the method to highly water-soluble amino acids such as L-glutamic acid is known. In addition, the medium must have low pH to precipitate L-glutamic acid. However, L-glutamic acid-producing bacteria such as those mentioned above cannot grow under acidic conditions, and therefore L-glutamic acid fermentation is performed under neutral conditions (U.S. Patent Nos. 3,220,929 and 3,032,474; Chao K.C. & Foster J.W., J. Bacteriol., 77, pp.715-725 (1959)). Thus, production of L-glutamic acid by fermentation accompanied by precipitation is not known. Furthermore, it is known that growth of most acidophile bacteria is inhibited by organic acids such as acetic acid, lactic acid and succinic acid (Yasuro Oshima Ed., "Extreme Environment Microorganism Handbook", p.231, Science Forum; Borichewski R.M., J. Bacteriol., 93, pp.597-599 (1967) etc.). Therefore, it is considered that many microorganisms are susceptible to L-glutamic acid, which is also an organic acid, under acidic conditions, and there has been no report that

search of microorganisms showing L-glutamic acid-producing ability under acidic conditions was attempted.

SUMMARY OF THE INVENTION

In the aforementioned current situation, an object of the present invention is to search and breed a microorganism that produces L-glutamic acid under low pH conditions and to provide a method for producing L-glutamic acid using an obtained microorganism by fermentation with precipitating L-glutamic acid.

The inventors of the present invention considered during the study for improvement of L-glutamic acid productivity by fermentation that inhibition of the production by L-glutamic acid accumulated in a medium at a high concentration was one of obstructions to the improvement of productivity. For example, cells have an excretory system and an uptake system for L-glutamic acid. However, if L-glutamic acid once excreted into the medium is incorporated into cells again, not only the production efficiency falls, but also the L-glutamic acid biosynthetic reactions are inhibited as a result. In order to avoid the inhibition of production by such accumulation of L-glutamic acid at high concentration, the inventors of the present invention screened microorganisms that can proliferate under acidic conditions and in the presence of a high concentration of L-glutamic acid. As a result, they successfully isolated microorganisms having such properties from a soil, and thus accomplished the present invention.

Thus, the present invention provides the followings.

(1) A microorganism which can metabolize a carbon source at a specific pH in a liquid medium containing L-glutamic acid at a saturation concentration and the carbon source, and has ability to accumulate L-glutamic acid in an amount exceeding the amount corresponding to the saturation concentration in the liquid medium at the pH.

(2) The microorganism according to (1), which can grow in the liquid medium.

(3) The microorganism according to (1) or (2), wherein the pH is not more than 5.0.

(4) The microorganism according to any one of (1) to (3), which has at least one of the following characteristics:

(a) the microorganism is enhanced in activity of an enzyme that catalyzes a reaction for biosynthesis of L-glutamic acid; and

(b) the microorganism is decreased in or deficient in activity of an enzyme that catalyzes a reaction branching from a biosynthetic pathway of L-glutamic acid and producing a compound other than L-glutamic acid.

(5) The microorganism according to (4), wherein the enzyme that catalyzes the reaction for biosynthesis of L-glutamic acid is at least one selected from citrate synthase, phosphoenolpyruvate carboxylase and glutamate dehydrogenase.

(6) The microorganism according to (4) or (5), wherein the enzyme that catalyzes the reaction branching from the biosynthetic pathway of L-glutamic acid and producing a

compound other than L-glutamic acid is α-ketoglutarate dehydrogenase.

(7) The microorganism according to any one of (1) to (6), wherein the microorganism belongs to the genus *Enterobacter*.

(8) The microorganism according to (7), which is *Enterobacter agglomerans*.

(9) The microorganism according to (8), which has a mutation that causes less extracellular secretion of a viscous material compared with a wild strain when cultured in a medium containing a saccharide.

(10) A method for producing L-glutamic acid by fermentation, which comprises culturing a microorganism as defined in any one of (1) to (9) in a liquid medium of which pH is adjusted to a pH at which L-glutamic acid is precipitated, to produce and accumulate L-glutamic acid and precipitate L-glutamic acid in the medium.

(11) A method for screening a microorganism suitable for producing L-glutamic acid by fermentation with precipitating L-glutamic acid in a liquid medium, which comprises inoculating a sample containing microorganisms into an acidic medium containing L-glutamic acid at a saturation concentration and a carbon source, and selecting a strain that can metabolize the carbon source.

(12) The method according to (11), wherein a strain that can grow in the medium is selected as the strain that can metabolize the carbon source.

(13) The method according to (11) or (12), wherein a pH of the medium is not more than 5.0.

According to the method of the present invention, L-glutamic acid can be produced by fermentation with precipitating L-glutamic acid. As a result, L-glutamic acid in the medium is maintained below a certain concentration, and L-glutamic acid can be produced without suffering from the product inhibition by L-glutamic acid at a high concentration.

BRIEF EXPLANATION OF THE DRAWINGS

Fig. 1 shows a restriction map of a DNA fragment derived from *Enterobacter agglomerans* pTWVEK101.

Fig. 2 shows comparison of the amino acid sequence deduced from the nucleotide sequence of the *sucA* gene derived from *Enterobacter agglomerans* and that derived from *Escherichia coli*. Upper sequence: *Enterobacter agglomerans*, lower sequence: *Escherichia coli* (the same shall apply hereafter).

Fig. 3 shows comparison of the amino acid sequence deduced from the nucleotide sequence of the *sucB* gene derived from *Enterobacter agglomerans* and that derived from *Escherichia coli*.

Fig. 4 shows comparison of the amino acid sequence deduced from the nucleotide sequence of the *sdhB* gene derived from *Enterobacter agglomerans* and that derived from *Escherichia coli*.

Fig. 5 shows comparison of the amino acid sequence deduced from the nucleotide sequence of the *sucC* gene derived from *Enterobacter agglomerans* and that derived from

Escherichia coli.

Fig. 6 shows construction of plasmid pMWCPG having a *gltA* gene, a *ppc* gene and a *gdhA* gene.

Fig. 7 shows construction of plasmid RSF-Tet having the replication origin of the broad host spectrum plasmid RSF1010 and a tetracycline resistance gene.

Fig. 8 shows construction of plasmid RSFCPG having the replication origin of the broad host spectrum plasmid RSF1010, a tetracycline resistance gene, a *gltA* gene, a *ppc* gene and a *gdhA* gene.

Fig. 9 shows construction of plasmid pSTVCB having a *gltA* gene.

DETAILED DESCRIPTION OF THE INVENTION

Hereafter, the present invention will be explained in detail.

The microorganism of the present invention is a microorganism that (1) can metabolize a carbon source at a specific pH in a liquid medium containing L-glutamic acid at a saturation concentration and the carbon source and (2) has ability to accumulate L-glutamic acid in an amount exceeding the amount corresponding to the saturation concentration in the liquid medium at the pH.

The term "saturation concentration" means a concentration of L-glutamic acid dissolved in a liquid medium when the liquid medium is saturated with L-glutamic acid.

Hereafter, a method for screening a microorganism that can metabolize a carbon source in a liquid medium containing

L-glutamic acid at a saturation concentration and the carbon source at a specific pH will be described. A sample containing microorganisms is inoculated into a liquid medium containing L-glutamic acid at a saturation concentration and a carbon source at a specific pH, and a strain that can metabolize the carbon source is selected. The specific pH is not particularly limited, but is usually not more than about 5.0, preferably not more than about 4.5, more preferably not more than about 4.3. The microorganism of the present invention is used to produce L-glutamic acid by fermentation with precipitating L-glutamic acid. If the pH is too high, it becomes difficult to allow the microorganism to produce L-glutamic acid enough for precipitation. Therefore, pH is preferably in the aforementioned range.

If pH of an aqueous solution containing L-glutamic acid is lowered, the solubility of L-glutamic acid significantly falls around pKa of γ-carboxyl group (4.25, 25°C). The solubility becomes the lowest at the isoelectric point (pH 3.2) and L-glutamic acid exceeding the amount corresponding to the saturation concentration is precipitated. While it depends on the medium composition, L-glutamic acid is usually dissolved in an amount of 10 to 20 g/L at pH 3.2, 30 to 40 g/L at pH 4.0 and 50 to 60 g/L at pH 4.7, at about 30°C. Usually pH does not need to be made below 3.0, because the L-glutamic acid precipitating effect plateaus when pH goes below a certain value. However, pH may be below 3.0.

In addition, the expression that a microorganism "can metabolize the carbon source" means that it can proliferate

or can consume the carbon source even though it cannot proliferate, that is, it indicates that it catabolizes carbon sources such as saccharides or organic acids. Specifically, for example, if a microorganism proliferates when cultured in a liquid medium containing L-glutamic acid at a saturation concentration at pH 5.0 to 4.0, preferably pH 4.5 to 4.0, more preferably pH 4.3 to 4.0, still more preferably pH 4.0 at an appropriate temperature, for example, 28°C, 37°C or 50°C for 2 to 4 days, this microorganism can metabolize the carbon source in the medium. Further, for example, even if a microorganism does not proliferate when it is cultured in a liquid medium containing L-glutamic acid at a saturation concentration at pH 5.0 to 4.0, preferably pH 4.5 to 4.0, more preferably pH 4.3 to 4.0, still more preferably pH 4.0 at an appropriate temperature, for example, 28°C, 37°C or 50°C for 2 to 4 days, the microorganism which consumes the carbon source in the medium is that can metabolize the carbon source in the medium.

The microorganism which can metabolize the carbon source includes a microorganism which can grow in the liquid medium.

The expression that a microorganism "can grow" means that it can proliferate or can produce L-glutamic acid even though it cannot proliferate. Specifically, for example, if a microorganism proliferates when cultured in a liquid medium containing L-glutamic acid at a saturation concentration at pH 5.0 to 4.0, preferably pH 4.5 to 4.0, more preferably pH 4.3 to 4.0, still more preferably pH 4.0

at an appropriate temperature, for example, 28°C, 37°C or 50°C for 2 to 4 days, this microorganism can grow in the medium. Further, for example, even if a microorganism does not proliferate when it is cultured in a liquid synthetic medium containing L-glutamic acid at a saturation concentration at pH 5.0 to 4.0, preferably pH 4.5 to 4.0, more preferably pH 4.3 to 4.0, still more preferably pH 4.0 at an appropriate temperature, for example, 28°C, 37°C or 50°C for 2 to 4 days, the microorganism which increases the amount of L-glutamic acid in the medium is that can grow in the medium.

The selection described above may be repeated two or more times under the same conditions or with changing pH or the concentration of L-glutamic acid. An initial selection can be performed in a medium containing L-glutamic acid at a concentration lower than the saturation concentration, and thereafter a subsequent selection can be performed in a medium containing L-glutamic acid at a saturation concentration. Further, strains with favorable properties such as superior proliferation rate may be selected.

In addition to the property described above, the microorganism of the present invention has ability to accumulate L-glutamic acid in an amount exceeding the amount corresponding to the saturation concentration of L-glutamic acid in a liquid medium. The pH of the aforementioned liquid medium is preferably the same as or close to that of the medium used for screening a microorganism having the aforementioned property (1). Usually, a microorganism becomes susceptible to L-glutamic acid at a high concentration as pH becomes lower.

Therefore, it is preferred that pH is not low from the viewpoint of resistance to L-glutamic acid, but low pH is preferred from the viewpoint of production of L-glutamic acid with precipitating it. To satisfy these conditions, pH may be in the range of 3 to 5, preferably 4 to 5, more preferably 4.0 to 4.7, still more preferably 4.0 to 4.5, particularly preferably 4.0 to 4.3.

As the microorganism of the present invention or breeding materials therefor, there can be mentioned, for example, microorganisms belonging to the genus *Enterobacter*, *Klebsiella*, *Serratia*, *Pantoea*, *Erwinia*, *Escherichia*, *Corynebacterium*, *Alicyclobacillus*, *Bacillus*, *Saccharomyces* or the like. Among these, microorganisms belonging to the genus *Enterobacter* are preferred. Hereafter, the microorganism of the present invention will be explained mainly for microorganisms belonging to the genus *Enterobacter*, but the present invention can be applied to microorganism belonging to other genera and not limited to the genus *Enterobacter*.

As microorganisms belonging to the *Enterobacter*, there can be specifically mentioned *Enterobacter agglomerans*, preferably the *Enterobacter agglomerans* AJ13355 strain. This strain was isolated from a soil in Iwata-shi, Shizuoka, Japan as a strain that can proliferate in a medium containing L-glutamic acid and a carbon source at low pH.

The physiological properties of AJ13355 are as follows:

(1) Gram staining: negative

(2) Behavior against oxygen: facultative anaerobic

(3) Catalase: positive

(4) Oxidase: negative

(5) Nitrate-reducing ability: negative

(6) Voges-Proskauer test: positive

(7) Methyl Red test: negative

(8) Urease: negative

(9) Indole production: positive

(10) Motility: motile

(11) H_2S production in TSI medium: weakly active

(12) β-galactosidase: positive

(13) Saccharide-assimilating property:

Arabinose: positive

Sucrose: positive

Lactose: positive

Xylose: positive

Sorbitol: positive

Inositol: positive

Trehalose: positive

Maltose: positive

Glucose: positive

Adonitol: negative

Raffinose: positive

Salicin: negative

Melibiose: positive

(14) Glycerol-assimilating property: positive

(15) Organic acid-assimilating property:

Citric acid: positive

Tartaric acid: negative

Gluconic acid: positive

Acetic acid: positive

Malonic acid: negative

(16) Arginine dehydratase: negative

(17) Ornithine decarboxylase: negative

(18) Lysine decarboxylase: negative

(19) Phenylalanine deaminase: negative

(20) Pigment formation: yellow

(21) Gelatin liquefaction ability: positive

(22) Growth pH: growth is possible at pH 4.0, good growth at pH 4.5 to 7

(23) Growth temperature: good growth at 25°C, good growth at 30°C, good growth at 37°C, growth is possible at 42°C, growth is not possible at 45°C

Based on these bacteriological properties, AJ13355 was determined as *Enterobacter agglomerans*.

The *Enterobacter agglomerans* AJ13355 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code: 305-8566, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki, Japan) on February 19, 1998 and received an accession number of FERM P-16644. It was then transferred to an international deposition under the provisions of Budapest Treaty on January 11, 1999 and received an accession number of FERM BP-6614.

The microorganism of the present invention may be a

microorganism originally having L-glutamic acid-producing ability or one having L-glutamic acid-producing ability imparted or enhanced by breeding through use of mutation treatment, recombinant DNA techniques or the like.

L-Glutamic acid-producing ability can be imparted or enhanced by, for example, increasing activity of an enzyme that catalyzes a reaction for biosynthesis of L-glutamic acid. L-Glutamic acid-producing ability can also be enhanced by decreasing activity of an enzyme that catalyzes a reaction branching from the biosynthetic pathway of L-glutamic acid and producing a compound other than L-glutamic acid, or making the activity deficient.

As enzymes that catalyze a reaction for biosynthesis of L-glutamic acid, there can be mentioned glutamate dehydrogenase (hereafter, also referred to as "GDH"), glutamine synthetase, glutamate synthase, isocitrate dehydrogenase, aconitate hydratase, citrate synthase (hereafter, also referred to as "CS"), phosphoenolpyruvate carboxylase (hereafter, also referred to as "PEPC"), pyruvate dehydrogenase, pyruvate kinase, enolase, phosphoglyceromutase, phosphoglycerate kinase, glyceraldehyde-3-phosphate dehydrogenase, triosephosphate isomerase, fructose bisphosphate aldolase, phosphofructokinase, glucose phosphate isomerase and so forth. Among these enzymes, one, two or three of CS, PEPC and GDH are preferred. Further, it is preferred that the activities of all the three enzymes, CS, PEPC and GDH, are enhanced in the microorganism of the present invention. In

particular, CS of *Brevibacterium lactofermentum* is preferred, because it does not suffer from inhibition by α-ketoglutaric acid, L-glutamic acid and NADH.

In order to enhance the activity of CS, PEPC or GDH, for example, a gene coding for CS, PEPC or GDH may be cloned on an appropriate plasmid and a host microorganism may be transformed with the obtained plasmid. The copy number of the gene coding for CS, PEPC or GDH (hereafter, abbreviated as "*gltA* gene", "*ppc* gene" and "*gdhA* gene", respectively) in the transformed strain cell increases, resulting in the increase of the activity of CS, PEPC or GDH.

The cloned *gltA* gene, *ppc* gene and *gdhA* gene are introduced into the aforementioned starting parent strain solely or in combination of arbitrary two or three kinds of them. When two or three kinds of the genes are introduced, two or three kinds of the genes may be cloned on one kind of plasmid and introduced into the host, or separately cloned on two or three kinds of plasmids that can coexist and introduced into the host.

Two or more kinds of genes coding for enzymes of the same kind, but derived from different microorganisms may be introduced into the same host.

The plasmids described above are not particularly limited so long as they are autonomously replicable in cells of a microorganism belonging to, for example, the genus *Enterobacter* or the like, but, for example, there can be mentioned pUC19, pUC18, pBR322, pHSG299, pHSG298, pHSG399, pH SG398, RSF1010, pMW119, pMW118, pMW219, pMW218, pACYC177,

pACYC184 and so forth. Besides these, vectors of phage DNA can also be used.

Transformation can be performed by, for example, the method of D.M. Morrison (Methods in Enzymology, 68, 326 (1979)), the method wherein permeability of DNA is increased by treating recipient bacterium cells with calcium chloride (Mandel M. and Higa A., J. Mol. Biol., 53, 159 (1970)), the electroporation (Miller J.H., "A Short Course in Bacterial Genetics", Cold Spring Harbor Laboratory Press, U.S.A. 1992) or the like.

The activity of CS, PEPC or GDH can also be increased by allowing multiple copies of a *gltA* gene, a *ppc* gene or a *gdhA* gene to be present on chromosomal DNA of the aforementioned starting parent strain to be a host. In order to introduce multiple copies of the *gltA* gene, the *ppc* gene or the *gdhA* gene on chromosomal DNA of a microorganism belonging to the genus *Enterobacter* or the like, a sequence of which multiple copies are present on the chromosomal DNA, such as repetitive DNA and inverted repeats present at termini of a transposable element, can be used. Alternatively, multiple copies of the genes can be introduced onto chromosomal DNA by utilizing transfer of a transposon containing the *gltA* gene, the *ppc* gene or the *gdhA* gene. As a result, the copy number of the *gltA* gene, the *ppc* gene or the *gdhA* gene in a transformed strain cell is increased, and thus the activity of CS, PEPC or GDH is increased.

As organisms to be a source of the *gltA* gene, the *ppc* gene or the *gdhA* gene of which copy number is increased, any

organism can be used so long as it has activity of CS, PEPC or GDH. Inter alia, bacteria, which are prokaryotes, for example, those belonging to the genus *Enterobacter, Klebsiella, Erwinia, Pantoea, Serratia, Escherichia, Corynebacterium, Brevibacterium* and *Bacillus* are preferred. As specific examples, there can be mentioned *Escherichia coli, Brevibacterium lactofermentum* and so forth. The *gltA* gene, the *ppc* gene and the *gdhA* gene can be obtained from chromosomal DNA of the microorganisms described above.

The *gltA* gene, the *ppc* gene and the *gdhA* gene can be obtained by using a mutant strain which is deficient in the activity of CS, PEPC or GDH to isolate a DNA fragment which complements the auxotrophy from chromosomal DNA of the aforementioned microorganisms. Since the nucleotide sequences of these genes of *Escherichia* and *Corynebacterium* bacteria have already been elucidated (Biochemistry, 22, pp.5243-5249 (1983); J. Biochem., 95, pp.909-916 (1984); Gene, 27, pp.193-199 (1984); Microbiology, 140, pp.1817-1828 (1994); Mol. Gen. Genet., 218, pp.330-339 (1989); Molecular Microbiology, 6, pp.317-326 (1992)), they can also be obtained by PCR utilizing primers synthesized based on each nucleotide sequence and chromosomal DNA as a template.

The activity of CS, PEPC or GDH can also be increased by enhancing the expression of the *gltA* gene, the *ppc* gene or the *gdhA* gene besides the aforementioned amplification of the genes. For example, the expression can be enhanced by replacing a promoter for the *gltA* gene, the *ppc* gene or the *gdhA* gene with other stronger promoters. For example,

lac promoter, *trp* promoter, *trc* promoter, *tac* promoter, P_R promoter and P_L promoter of the lamda phage and so forth are known as strong promoters. The *gltA* gene, the *ppc* gene and the *gdhA* gene of which promoter is replaced are cloned on a plasmid and introduced into the host microorganism, or introduced onto the chromosomal DNA of the host microorganism by using repetitive DNA, inverted repeats, transposon or the like.

The activity of CS, PEPC or GDH can also be enhanced by replacing the promoter of the *gltA* gene, the *ppc* gene or the *gdhA* gene on the chromosome with other stronger promoters (see WO 87/03006 and Japanese Patent Application Laid-open No. 61-268183), or inserting a strong promoter in the upstream of the coding sequence of each gene (see Gene, 29, pp.231-241 (1984)). Specifically, homologous recombination can be performed between DNA containing the *gltA* gene, the *ppc* gene or the *gdhA* gene of which promoter is replaced with a stronger one or a part thereof and the corresponding gene on the chromosome.

Examples of the enzyme which catalyze a reaction branching from the biosynthetic pathway of the L-glutamic acid and producing a compound other than L-glutamic acid include α-ketoglutarate dehydrogenase (hereafter, also referred to as "αKGDH"), isocitrate lyase, phosphate acetyltransferase, acetate kinase, acetohydroxy acid synthase, acetolactate synthase, formate acetyltransferase, lactate dehydrogenase, glutamate decarboxylase, 1-pyrroline dehydrogenase and so forth. Among these enzymes,

αKGDH is preferred.

In order to obtain decrease or deficiency of the activity of the aforementioned enzyme in a microorganism belonging to the genus *Enterobacter* or the like, mutation causing decrease or deficiency of the intracellular activity of the enzyme can be introduced into the gene of the aforementioned enzyme by a usual mutagenesis or genetic engineering method.

Examples of the mutagenesis method include, for example, methods utilizing irradiation with X-ray or ultraviolet ray, methods utilizing treatment with a mutagenic agent such as N-methyl-N'-nitro-N-nitrosoguanidine, and so forth. The site where the mutation is introduced to the gene may be in a coding region coding for an enzyme protein, or a region for regulating expression such as a promoter.

Examples of the genetic engineering methods include, for example, methods utilizing gene recombination, transduction, cell fusion and so forth. For example, a drug resistance gene is inserted into a cloned target gene to prepare a gene that has lost its function (defective gene). Subsequently, this defective gene is introduced into a cell of a host microorganism, and the target gene on the chromosome is replaced with the aforementioned defective gene by utilizing homologous recombination (gene disruption).

Decrease or deficiency of intracellular activity of the target enzyme and the degree of decrease of the activity can be determined by measuring the enzyme activity of a cell

extract or a purified fraction thereof obtained from a candidate strain and comparing with that of a wild strain. For example, the αKGDH activity can be measured by the method of Reed et al. (Reed L.J. and Mukherjee B.B., Methods in Enzymology, 13, pp.55-61 (1969)).

Depending on the target enzyme, the target mutant strain can be selected based on the phenotype of the mutant strain. For example, a mutant strain which is deficient in the αKGDH activity or decreases in the αKGDH activity cannot proliferate or shows a markedly reduced proliferation rate in a minimal medium containing glucose or a minimal medium containing acetic acid or L-glutamic acid as an exclusive carbon source under aerobic conditions. However, normal proliferation is enabled even under the same condition by adding succinic acid or lysine, methionine and diaminopimelic acid to a minimal medium containing glucose. By utilizing these phenomena as indicators, mutant strains with decreased αKGDH activity or deficient in the activity can be selected.

A method for preparing the αKGDH gene deficient strain of *Brevibacterium lactofermentum* by utilizing homologous recombination is described in detail in WO 95/34672. Similar methods can be applied to the other microorganisms.

Further, techniques such as cloning of genes and cleavage and ligation of DNA, transformation and so forth are described in detail in Molecular Cloning, 2nd Edition, Cold Spring Harbor Press, 1989 and so forth.

As a specific example of a mutant strain deficient in

αKGDH activity or with decreased αKGDH activity obtained as described above, there can be mentioned *Enterobacter agglomerans* AJ13356. *Enterobacter agglomerans* AJ13356 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code: 305-8566, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki, Japan) on February 19, 1998 and received an accession number of FERM P-16645. It was then transferred to an international deposition under the provisions of Budapest Treaty on January 11, 1999 and received an accession number of FERM BP-6615. The *Enterobacter agglomerans* AJ13356 is deficient in αKGDH activity as a result of disruption of the αKGDH-E1 subunit gene (*sucA*).

When *Enterobacter agglomerans*, an example of the microorganism used in the present invention, is cultured in a medium containing a saccharide, a viscous material is extracellularly secreted, resulting in low operation efficiency. Therefore, when *Enterobacter agglomerans* having such a property of secreting the viscous material is used, it is preferable to use a mutant strain that secretes less the viscous material compared with a wild strain. Examples of mutagenesis methods include, for example, methods utilizing irradiation with X ray or ultraviolet ray, method utilizing treatment with a mutagenic agent such as N-methyl-N'-nitro-N-nitrosoguanidine and so forth. A mutant strain with decreased secretion of the viscous material can be selected by inoculating mutagenized

bacterial cells in a medium containing a saccharide, for example, LB medium plate containing 5 g/L of glucose, culturing them with tilting the plate about 45 degrees and selecting a colony which does not show flowing down of liquid.

In the present invention, impartation or enhancement of L-glutamic acid-producing ability and impartation of other favorable properties such as mutation for less viscous material secretion described above can be carried out in an arbitrary order.

By culturing the microorganism of the present invention in a liquid medium of which pH is adjusted to a pH at which L-glutamic acid is precipitated, L-glutamic acid can be produced and accumulated with precipitating it in the medium. L-Glutamic acid can also be precipitated by starting the culture at a neutral pH and then ending it at a pH at which L-glutamic acid is precipitated.

The pH at which L-glutamic acid is precipitated means one at which L-glutamic acid is precipitated when the microorganism produces and accumulates L-glutamic acid.

As the aforementioned medium, a usual nutrient medium containing a carbon source, a nitrogen source, mineral salts and organic trace nutrients such as amino acids and vitamins as required can be used so long as pH is adjusted to a pH at which L-glutamic acid is precipitated. Either a synthetic medium or a natural medium can be used. The carbon source and the nitrogen source used in the medium can be any ones so long as they can be used by the cultured strain.

As the carbon source, saccharides such as glucose,

glycerol, fructose, sucrose, maltose, mannose, galactose, starch hydrolysate and molasses are used. In addition, organic acids such as acetic acid and citric acid may be used each alone or in combination with another carbon source.

As the nitrogen source, ammonia, ammonium salts such as ammonium sulfate, ammonium carbonate, ammonium chloride, ammonium phosphate and ammonium acetate, nitrates and so forth are used.

As the organic trace nutrients, amino acids, vitamins, fatty acids, nucleic acids, those containing these substances such as peptone, casamino acid, yeast extract and soybean protein decomposition products are used. When an auxotrophic mutant strain that requires an amino acid and so forth for metabolization or growth is used, the required nutrient must be supplemented.

As mineral salts, phosphates, magnesium salts, calcium salts, iron salts, manganese salts and so forth are used.

As for the culture method, aeration culture is usually performed with controlling the fermentation temperature to be 20 to 42°C and pH to be 3 to 5, preferably 4 to 5, more preferably 4 to 4.7, particularly preferably 4 to 4.5. Thus, after about 10 hours to 4 days of culture, a substantial amount of L-glutamic acid is accumulated in the culture. Accumulated L-glutamic acid exceeding the amount corresponding to the saturation concentration is precipitated in the medium.

After completion of the culture, L-glutamic acid precipitated in the culture can be collected by

centrifugation, filtration or the like. L-Glutamic acid dissolved in the medium can be collected according to known methods. For example, the L-glutamic acid can be isolated by concentrating the culture broth to crystallize it or isolated by ion exchange chromatography or the like. L-Glutamic acid precipitated in the culture broth may be isolated together with L-glutamic acid that have been dissolved in the medium after it is crystallized.

According to the method of the present invention, L-glutamic acid exceeding the amount corresponding to the saturation concentration is precipitated, and the concentration of L-glutamic acid dissolved in the medium is maintained at a constant level. Therefore, influence of L-glutamic acid at a high concentration on microorganisms can be reduced. Accordingly, it becomes possible to breed a microorganism having further improved L-glutamic acid-producing ability. Further, since L-glutamic acid is precipitated as crystals, acidification of the culture broth by accumulation of L-glutamic acid is suppressed, and therefore the amount of alkali used for maintaining pH of the culture can significantly be reduced.

EXAMPLES

Hereafter, the present invention will be more specifically explained with reference to the following examples.

<1> Screening of microorganism having L-glutamic acid resistance in acidic environment

Screening of a microorganism having L-glutamic acid resistance in an acidic environment was performed as follows. Each of about 500 samples obtained from nature including soil, fruits, plant bodies, river water in an amount of 1 g was suspended in 5 mL of sterilized water, of which 200 μL was coated on 20 mL of solid medium of which pH was adjusted to 4.0 with HCl. The composition of the medium was as follows: 3 g/L of glucose, 1 g/L of $(NH_4)_2SO_4$, 0.2 g/L of $MgSO_4 \cdot 7H_2O$, 0.5 g/L of KH_2PO_4, 0.2 g/L of NaCl, 0.1 g/L of $CaCl_2 \cdot 7H_2O$, 0.01 g/L of $FeSO_4 \cdot 7H_2O$, 0.01 g/L of $MnSO_4 \cdot 4H_2O$, 0.72 mg/L of $ZnSO_4 \cdot 2H_2O$, 0.64 mg/L of $CuSO_4 \cdot 5H_2O$, 0.72 mg/L of $CoCl_2 \cdot 6H_2O$, 0.4 mg/L of boric acid, 1.2 mg/L of $Na_2MoO_4 \cdot 2H_2O$, 50 μg/L of biotin, 50 μg/L of calcium pantothenate, 50 μg/L of folic acid, 50 μg/L of inositol, 50 μg/L of niacin, 50 μg/L of p-aminobenzoic acid, 50 μg/L of pyridoxine hydrochloride, 50 μg/L of riboflavin, 50 μg/L of thiamine hydrochloride, 50 mg/L of cycloheximide, 20 g/L of agar.

The media plated on which the above samples were plated were incubated at 28°C, 37°C or 50°C for 2 to 4 days and 378 strains each forming a colony were obtained.

Subsequently, each of the strains obtained as described above was inoculated in a test tube of 16.5 cm in length and 14 mm in diameter containing 3 mL of liquid medium (adjusted to pH 4.0 with HCl) containing a saturation concentration of L-glutamic acid and cultured at 28°C, 37°C or 50°C for 24 hours to 3 days with shaking. Then, the grown strains were selected. The composition of the aforementioned medium was follows: 40 g/L of glucose, 20 g/L

of $(NH_4)_2SO_4$, 0.5 g/L of $MgSO_4 \cdot 7H_2O$, 2 g/L of KH_2PO_4, 0.5 g/L of NaCl, 0.25 g/L of $CaCl_2 \cdot 7H_2O$, 0.02 g/L of $FeSO_4 \cdot 7H_2O$, 0.02 g/L of $MnSO_4 \cdot 4H_2O$, 0.72 mg/L of $ZnSO_4 \cdot 2H_2O$, 0.64 mg/L of $CuSO_4 \cdot 5H_2O$, 0.72 mg/L of $CoCl_2 \cdot 6H_2O$, 0.4 mg/L of boric acid, 1.2 mg/L of $Na_2MoO_4 \cdot 2H_2O$, 2 g/L of yeast extract.

Thus, 78 strains of microorganisms having L-glutamic acid resistance in an acidic environment were successfully obtained.

<2> Selection of strains with superior growth rate in acidic environment from microorganisms having L-glutamic acid resistance

The various microorganisms having L-glutamic acid resistance in an acidic environment obtained as described above were each inoculated into a test tube of 16.5 cm in length and 14 mm in diameter containing 3 mL of medium (adjusted to pH 4.0 with HCl) obtained by adding 20 g/L of glutamic acid and 2 g/L of glucose to M9 medium (Sambrook, J., Fritsh, E.F. and Maniatis, T., "Molecular Cloning", Cold Spring Harbor Laboratory Press, 1989), and the turbidity of the medium was measured in the time course to select strains with a favorable growth rate. As a result, as a strain showing favorable growth, the AJ13355 strain was obtained from a soil in Iwata-shi, Shizuoka, Japan. This strain was determined as *Enterobacter agglomerans* based on its bacteriological properties described above.

<3> Acquisition of strain with less viscous material

secretion from *Enterobacter agglomerans* AJ13355 strain

Since the *Enterobacter agglomerans* AJ13355 strain extracellularly secretes a viscous material when cultured in a medium containing a saccharide, operation efficiency is not favorable. Therefore, a strain with less viscous material secretion was obtained by the ultraviolet irradiation method (Miller, J.H. et al., "A Short Course in Bacterial Genetics; Laboratory Manual", p.150, Cold Spring Harbor Laboratory Press, 1992).

The *Enterobacter agglomerans* AJ13355 strain was irradiated with ultraviolet ray for 2 minutes at the position 60 cm away from a 60-W ultraviolet lamp and cultured in LB medium overnight to fix mutation. The mutagenized strain was diluted and inoculated in LB medium containing 5 g/L of glucose and 20 g/L of agar so that about 100 colonies per plate would emerge and cultured at 30°C overnight with tilting the plate about 45 degrees, and then 20 colonies showing no flowing down of the viscous material were selected.

As a strain satisfying conditions that no revertant emerged even after 5 times of subculture in LB medium containing 5 g/L of glucose and 20 g/L of agar, and that there should be observed growth equivalent to the parent strain in LB medium, LB medium containing 5 g/L of glucose and M9 medium (Sambrook, J. et al., Molecular Cloning, 2nd Edition, Cold Spring Harbor Press, 1989) to which 20 g/L of L-glutamic acid and 2 g/L of glucose were added and of which pH was adjusted to 4.5 with HCl, SC17 strain was selected from the

strains selected above.

<4> Construction of glutamic acid-producing bacterium from *Enterobacter agglomerans* SC17 strain

(1) Preparation of αKGDH deficient strain from *Enterobacter agglomerans* SC17 strain

A strain deficient in αKGDH and with enhanced L-glutamic acid biosynthetic system was prepared from the *Enterobacter agglomerans* SC17 strain.

(i) Cloning of αKGDH gene (hereafter, referred to as "*sucAB*") of *Enterobacter agglomerans* AJ13355 strain

The *sucAB* gene of the *Enterobacter agglomerans* AJ13355 strain was cloned by selecting a DNA fragment complementing the acetic acid-unassimilating property of the αKGDH-E1 subunit gene (hereafter, referred to as "*sucA*") deficient strain of *Escherichia coli* from chromosomal DNA of the *Enterobacter agglomerans* AJ13355 strain.

The chromosomal DNA of the *Enterobacter agglomerans* AJ13355 strain was isolated by a method usually employed when chromosomal DNA is extracted from *Escherichia coli* (Text for Bioengineering Experiments, Edited by the Society for Bioscience and Bioengineering, Japan, pp.97-98, Baifukan, 1992). The pTWV228 (resistant to ampicillin) used as a vector was commercially available one from Takara Shuzo Co., Ltd.

The chromosomal DNA of the AJ13355 strain digested with *Eco*T221 and pTWV228 digested with *Pst*I were ligated by using T4 ligase and used to transform the *sucA* deficient

Escherichia coli JRG465 strain (Herbert, J. et al., Mol. Gen. Genetics, 105, 182 (1969)). A strain growing in an acetate minimal medium was selected from the transformant strains obtained above, and a plasmid was extracted from it and designated as pTWVEK101. The *Escherichia coli* JRG465 strain harboring pTWVEK101 recovered auxotrophy for succinic acid or L-lysine and L-methionine besides the acetic acid-assimilating property. This suggests that pTWVEK101 contains the *sucA* gene of *Enterobacter agglomerans*.

Fig. 1 shows the restriction map of a DNA fragment derived from *Enterobacter agglomerans* in pTWVEK101. The determined nucleotide sequence of the hatched portion in Fig. 1 is shown as SEQ ID NO: 1. In this sequence, nucleotide sequences considered to be two full length ORFs and two nucleotide sequences considered to be partial sequences of the ORFs were found. SEQ ID NOS: 2 to 5 show amino acid sequences that can be encoded by these ORFs or partial sequences in an order from the 5′ end. As a result of homology search for these, it was revealed that the portion of which nucleotide sequences were determined contained a 3′-end partial sequence of the succinate dehydrogenase iron-sulfur protein gene (*sdhB*), full length *sucA* and αKGDH-E2 subunit gene (*sucB*), and 5′-end partial sequence of the succinyl CoA synthetase β subunit gene (*sucC*). The results of comparison of the amino acid sequences deduced from these nucleotide sequences with those derived from *Escherichia coli* (Eur. J. Biochem., 141, pp.351-359 (1984); Eur. J. Biochem., 141, pp.361-374 (1984); Biochemistry, 24, pp.6245-6252 (1985))

are shown in Figs. 2 to 5. Thus, the amino acid sequences each showed very high homology. In addition, it was found that a cluster of *sdhB-sucA-sucB-sucC* was constituted on the chromosome of *Enterobacter agglomerans* as in *Escherichia coli* (Eur. J. Biochem., 141, pp.351-359 (1984); Eur. J. Biochem., 141, pp.361-374 (1984); Biochemistry, 24, pp.6245-6252 (1985)).

(ii) Acquisition of αKGDH deficient strain derived from *Enterobacter agglomerans* SC17 strain

The homologous recombination was performed by using the *sucAB* gene of *Enterobacter agglomerans* obtained as described above to obtain an αKGDH deficient strain of *Enterobacter agglomerans*.

After pTWVEK101 was digested with *Sph*I to excise a fragment containing *sucA*, the fragment was blunt-ended with Klenow fragment (Takara Shuzo Co., Ltd.) and ligated with pBR322 digested with *Eco*RI and blunt-ended with Klenow fragment, by using T4 DNA ligase (Takara Shuzo Co., Ltd.). The obtained plasmid was digested at the restriction enzyme *Bgl*II recognition site positioned substantially at the center of *sucA* by using this enzyme, blunt-ended with Klenow fragment, and then ligated again by using T4 DNA ligase. It was considered that the *sucA* gene did not function because a frameshift mutation was introduced into *sucA* of the plasmid newly constructed through the above procedure.

The plasmid constructed as described above was digested with a restriction enzyme *Apa*LI, and subjected to

agarose gel electrophoresis to recover a DNA fragment containing *sucA* into which the frameshift mutation was introduced and a tetracycline resistance gene derived from pBR322. The recovered DNA fragment was ligated again by using T4 DNA ligase to construct a plasmid for disrupting the αKGDH gene.

The plasmid for disrupting the αKGDH gene obtained as described above was used to transform the *Enterobacter agglomerans* SC17 strain by electroporation (Miller, J.H., "A Short Course in Bacterial Genetics; Handbook", p.279, Cold Spring Harbor Laboratory Press, U.S.A., 1992), and a strain wherein *sucA* on the chromosome was replaced with a mutant type one by homologous recombination of the plasmid was obtained by using the tetracycline resistance as an indicator. The obtained strain was designated as SC17sucA strain.

In order to confirm that the SC17sucA strain was deficient in the αKGDH activity, the enzyme activity was measured by the method of Reed et al. (Reed, L.J. and Mukherjee, B.B., Methods in Enzymology, 13, pp.55-61, (1969)) by using cells of the strain cultured in LB medium until the logarithmic growth phase. As a result, αKGDH activity of 0.073 (ΔABS/min/mg protein) was detected from the SC17 strain, whereas no αKGDH activity was detected from the SC17sucA strain, and thus it was confirmed that the *sucA* was deficient as purposed.

(2) Enhancement of L-glutamic acid biosynthetic system of *Enterobacter agglomerans* SC17sucA strain

Subsequently, a citrate synthase gene, a phosphoenolpyruvate carboxylase gene and a glutamate dehydrogenase gene derived from *Escherichia coli* were introduced into the SC17sucA strain.

(i) Preparation of plasmid having *gltA* gene, *ppc* gene and *gdhA* gene derived from *Escherichia coli*

The procedures of preparing a plasmid having a *gltA* gene, a *ppc* gene and a *gdhA* gene will be explained by referring to Figs. 6 and 7.

A plasmid having a *gdhA* gene derived from *Escherichia coli*, pBRGDH (Japanese Patent Application Laid-open No. 7-203980), was digested with *Hin*dIII and *Sph*I, the both ends were blunt-ended by the T4 DNA polymerase treatment, and then the DNA fragment having the *gdhA* gene was purified and recovered. Separately, a plasmid having a *gltA* gene and a *ppc* gene derived from *Escherichia coli*, pMWCP (WO 97/08294), was digested with *Xba*I, and then the both ends were blunt-ended by using T4 DNA polymerase. This was mixed with the above purified DNA fragment having the *gdhA* gene and ligated by using T4 ligase to obtain a plasmid pMWCPG, which corresponded to pMWCP further containing the *gdhA* gene (Fig. 6).

At the same time, the plasmid pVIC40 (Japanese Patent Application Laid-open No. 8-047397) having the replication origin of the broad host spectrum plasmid RSF1010 was digested with *Not*I, treated with T4 DNA polymerase and digested with *Pst*I. pBR322 was digested with *Eco*T14I,

treated with T4 DNA polymerase and digested with *Pst*I. The both products were mixed and ligated by using T4 ligase to obtain a plasmid RSF-Tet having the replication origin of RSF1010 and a tetracycline resistance gene (Fig. 7).

Subsequently, pMWCPG was digested with *Eco*RI and *Pst*I, and a DNA fragment having the *gltA* gene, the *ppc* gene and the *gdhA* gene was purified and recovered. RSF-Tet was similarly digested with *Eco*RI and *Pst*I, and a DNA fragment having the replication origin of RSF1010 was purified and recovered. The both products were mixed and ligated by using T4 ligase to obtain a plasmid RSFCPG, which corresponded to RSF-Tet containing the *gltA* gene, the *ppc* gene and the *gdhA* gene (Fig. 8). It was confirmed that the obtained plasmid RSFCPG expressed the *gltA* gene, the *ppc* gene and the *gdhA* gene, by the complementation of the auxotrophy of the *gltA*, *ppc* or *gdhA* gene deficient strain derived from *Escherichia coli* and measurement of each enzyme activity.

(ii) Preparation of plasmid having *gltA* gene derived from *Brevibacterium lactofermentum*

A plasmid having the *gltA* gene derived from *Brevibacterium lactofermentum* was constructed as follows. PCR was performed by using the primer DNAs having the nucleotide sequences represented by SEQ ID NOS: 6 and 7, which were prepared based on the nucleotide sequence of the *Corynebacterium glutamicum gltA* gene (Microbiology, 140, pp.1817-1828 (1994)), and chromosomal DNA of *Brevibacterium lactofermentum* ATCC13869 as a template to obtain a *gltA* gene

fragment of about 3 kb. This fragment inserted into a plasmid pHSG399 (purchased from Takara Shuzo Co., Ltd.) digested with *Sma*I to obtain a plasmid pHSGCB (Fig. 9). Subsequently, pHSGCB was digested with *Hin*dIII, and the excised *gltA* gene fragment of about 3 kb was inserted into a plasmid pSTV29 (purchased from Takara Shuzo Co., Ltd.) digested with *Hin*dIII to obtain a plasmid pSTVCB (Fig. 9). It was confirmed that the obtained plasmid pSTVCB expressed the *gltA* gene, by measuring the enzyme activity in the *Enterobacter agglomerans* AJ13355 strain.

(iii) Introduction of RSFCPG and pSTVCB into SC17sucA strain

The *Enterobacter agglomerans* SC17sucA strain was transformed with RSFCPG by electroporation to obtain a transformant SC17sucA/RSFCPG strain having tetracycline resistance. Further, the SC17sucA/RSFCPG strain was transformed with pSTVCB by electroporation to obtain a transformant SC17sucA/RSFCPG+pSTVCB strain having chloramphenicol resistance.

<4> Acquisition of strain with improved resistance to L-glutamic acid in low pH environment

A strain with improved resistance to L-glutamic acid at a high concentration in a low pH environment (hereafter, also referred to as "high-concentration Glu-resistant strain at low pH") was isolated from the *Enterobacter agglomerans* SC17sucA/RSFCPG+pSTVCB strain.

The SC17sucA/RSFCPG+pSTVCB strain was cultured

overnight at 30°C in LBG medium (10 g/L of tryptone, 5 g/L of yeast extract, 10 g/L of NaCl, 5 g/L of glucose), and the cells washed with saline was appropriately diluted and plated on an M9-E medium (4 g/L of glucose, 17 g/L of $Na_2HPO_4 \cdot 12H_2O$, 3 g/L of KH_2PO_4, 0.5 g/L of NaCl, 1 g/L of NH_4Cl, 10 mM of $MgSO_4$, 10 μM of $CaCl_2$, 50 mg/L of L-lysine, 50 mg/L of L-methionine, 50 mg/L of DL-diaminopimelic acid, 25 mg/L of tetracycline, 25 mg/L of chloramphenicol, 30 g/L of L-glutamic acid, adjusted to pH 4.5 with aqueous ammonia) plate. The colony emerged after culture at 32°C for 2 days was obtained as a high-concentration Glu-resistant strain at low pH.

For the obtained strain, growth level in M9-E liquid medium was measured and L-glutamic acid-producing ability was tested in a 50-ml volume large test tube containing 5 ml of L-glutamic acid production test medium (40 g/L of glucose, 20 g/L of $(NH_4)_2SO_4$, 0.5 g/L of $MgSO_4 \cdot 7H_2O$, 2 g/L of KH_2PO_4, 0.5 g/L of NaCl, 0.25 g/L of $CaCl_2 \cdot 7H_2O$, 0.02 g/L of $FeSO_4 \cdot 7H_2O$, 0.02 g/L of $MnSO_4 \cdot 4H_2O$, 0.72 mg/L of $ZnSO_4 \cdot 2H_2O$, 0.64 mg/L of $CuSO_4 \cdot 5H_2O$, 0.72 mg/L of $CoCl_2 \cdot 6H_2O$, 0.4 mg/L of boric acid, 1.2 mg/L of $Na_2MoO_4 \cdot 2H_2O$, 2 g/L of yeast extract, 200 mg/L of L-lysine hydrochloride, 200 mg/L of L-methionine, 200 mg/L of DL-α,ε-diaminopimelic acid, 25 mg/L of tetracycline hydrochloride, 25 mg/L of chloramphenicol). A strain that exhibited the best growth level and the same L-glutamic acid producing ability as that of its parent strain, the SC17/RSFCPG+pSTVCB strain, was designated as *Enterobacter agglomerans* AJ13601. The AJ13601 strain was

deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code: 305-8566, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki, Japan) on August 18, 1999 and received an accession number of FERM P-17516. It was then transferred to an international deposition under the provisions of Budapest Treaty on July 6, 2000 and received an accession number of FERM BP-7207.

<5> Culture of *Enterobacter agglomerans* AJ13601 strain for L-glutamic acid production (1)

The *Enterobacter agglomerans* AJ13601 strain was inoculated into a 1-L jar fermenter containing 300 ml of medium containing 40 g/L of glucose, 20 g/L of $(NH_4)_2SO_4$, 0.5 g/L of $MgSO_4 \cdot 7H_2O$, 2 g/L of KH_2PO_4, 0.5 g/L of NaCl, 0.25 g/L of $CaCl_2 \cdot 7H_2O$, 0.02 g/L of $FeSO_4 \cdot 7H_2O$, 0.02 g/L of $MnSO_4 \cdot 4H_2O$, 0.72 mg/L of $ZnSO_4 \cdot 2H_2O$, 0.64 mg/L of $CuSO_4 \cdot 5H_2O$, 0.72 mg/L of $CoCl_2 \cdot 6H_2O$, 0.4 mg/L of boric acid, 1.2 mg/L of $Na_2MoO_4 \cdot 2H_2O$, 2 g/L of yeast extract, 200 mg/L of L-lysine hydrochloride, 200 mg/L of L-methionine, 200 mg/L of DL-α,ε-diaminopimelic acid, 25 mg/L of tetracycline hydrochloride and 25 mg/L of chloramphenicol, and cultured at 34°C and pH 6.0 for 14 hours. The culture pH was controlled by introducing ammonia gas into the medium.

The culture obtained as described above was centrifuged at 5000 rpm for 10 minutes, and the collected cells were inoculated into a 1-L jar fermenter containing

300 ml of medium containing 40 g/L of glucose, 5 g/L of $(NH_4)_2SO_4$, 1.5 g/L of $MgSO_4 \cdot 7H_2O$, 6 g/L of KH_2PO_4, 1.5 g/L of NaCl, 0.75 g/L of $CaCl_2 \cdot 7H_2O$, 0.06 g/L of $FeSO_4 \cdot 7H_2O$, 0.06 g/L of $MnSO_4 \cdot 4H_2O$, 2.16 mg/L of $ZnSO_4 \cdot 2H_2O$, 1.92 mg/L of $CuSO_4 \cdot 5H_2O$, 2.16 mg/L of $CoCl_2 \cdot 6H_2O$, 1.2 mg/L of boric acid, 3.6 mg/L of $Na_2MoO_4 \cdot 2H_2O$, 6 g/L of yeast extract, 600 mg/L of L-lysine hydrochloride, 600 mg/L of L-methionine, 600 mg/L of DL-α,ε-diaminopimelic acid, 25 mg/L of tetracycline hydrochloride and 25 mg/L of chloramphenicol and cultured at 34°C and pH 4.5 to perform culture for L-glutamic acid production. The culture pH was controlled by introducing ammonia gas into the medium. As the initially added glucose was depleted, 600 g/L of glucose was continuously added.

As a result of the culture for L-glutamic acid production performed for 50 hours as described above, a substantial amount of L-glutamic acid crystals were precipitated in the jar fermenter. Table 1 shows the concentration of L-glutamic acid dissolved in the culture broth at that time and the L-glutamic acid concentration measured by dissolving the crystals in 2 M potassium hydroxide. L-Glutamic acid crystals were collected from the culture by decantation after the culture was left stood.

Table 1

Concentration of L-glutamic acid dissolved in culture broth	51 g/L
Amount of L-glutamic acid precipitated as crystals	67 g/L
Concentration of L-glutamic acid measured by dissolving crystals	118 g/L

<6> Culture of *Enterobacter agglomerans* AJ13601 strain for L-glutamic acid production (2)

The following experiment was performed in order to confirm that the *Enterobacter agglomerans* AJ13601 strain still had L-glutamic acid-producing ability even under the condition that L-glutamic acid crystals were present.

The *Enterobacter agglomerans* AJ13601 strain was inoculated into a 1-L jar fermenter containing 300 ml of medium containing 40 g/L of glucose, 20 g/L of $(NH_4)_2SO_4$, 0.5 g/L of $MgSO_4 \cdot 7H_2O$, 2 g/L of KH_2PO_4, 0.5 g/L of NaCl, 0.25 g/L of $CaCl_2 \cdot 7H_2O$, 0.02 g/L of $FeSO_4 \cdot 7H_2O$, 0.02 g/L of $MnSO_4 \cdot 4H_2O$, 0.72 mg/L of $ZnSO_4 \cdot 2H_2O$, 0.64 mg/L of $CuSO_4 \cdot 5H_2O$, 0.72 mg/L of $CoCl_2 \cdot 6H_2O$, 0.4 mg/L of boric acid, 1.2 mg/L of $Na_2MoO_4 \cdot 2H_2O$, 2 g/L of yeast extract, 200 mg/L of L-lysine hydrochloride, 200 mg/L of L-methionine, 200 mg/L of DL-α,ε-diaminopimelic acid, 25 mg/L of tetracycline hydrochloride and 25 mg/L of chloramphenicol, and cultured at 34°C at pH 6.0 for 14 hours. The culture pH was controlled by bubbling the medium with ammonia gas. The culture obtained as described above was centrifuged at 5000 rpm for 10 minutes, and then the collected cells were cultured in a medium where L-glutamic acid was present as crystals. The used medium contained 40 g/L of glucose, 5 g/L of $(NH_4)_2SO_4$, 1.5 g/L of $MgSO_4 \cdot 7H_2O$, 6 g/L of KH_2PO_4, 1.5 g/L of NaCl, 0.75 g/L of $CaCl_2 \cdot 7H_2O$, 0.06 g/L of $FeSO_4 \cdot 7H_2O$, 0.06 g/L of $MnSO_4 \cdot 4H_2O$, 2.16 mg/L of $ZnSO_4 \cdot 2H_2O$, 1.92 mg/L of $CuSO_4 \cdot 5H_2O$, 2.16 mg/L of $CoCl_2 \cdot 6H_2O$, 1.2 mg/L of boric acid, 3.6 mg/L of $Na_2MoO_4 \cdot 2H_2O$, 6 g/L of yeast extract, 600

mg/L of L-lysine hydrochloride, 600 mg/L of L-methionine, 600 mg/L of DL-α,ε-diaminopimelic acid, 25 mg/L of tetracycline hydrochloride and 25 mg/L of chloramphenicol and L-glutamic acid crystals were added to 40 g/L. The cells were inoculated in a 1-L jar fermenter containing 300 ml of this medium and cultured at 34°C and pH 4.3 to perform culture for L-glutamic acid production. The culture pH was controlled by introducing ammonia gas into the medium. As the initially added glucose was depleted, 600 g/L of glucose was continuously added. In this medium, only 39 g/L of the added L-glutamic acid was dissolved at pH 4.3 and the remaining 1 g/L was present as crystals.

As a result of the culture for L-glutamic acid production performed for 53 hours as described above, a substantial amount of L-glutamic acid crystals were precipitated in the jar fermenter. Table 2 shows the concentration of L-glutamic acid dissolved in the culture broth, the amount of L-glutamic acid present as crystals at that time and the L-glutamic acid concentration measured by dissolving the crystals in 2 M KOH solution. L-Glutamic acid crystals were collected from the culture by decantation after the culture was left stood. The results showed that the *Enterobacter agglomerans* AJ13601 strain accumulated L-glutamic acid and precipitated crystals thereof even under the condition that L-glutamic acid crystals were present.

Table 2

Concentration of L-glutamic acid dissolved in culture broth	39 g/L
Amount of L-glutamic acid precipitated as crystals	119 g/L
Concentration of L-glutamic acid measured by dissolving crystals	158 g/L
Amount of L-glutamic acid crystals newly produced by main culture	118 g/L

<7> Culture of *Enterobacter agglomerans* AJ13601 strain for L-glutamic acid production (3)

The *Enterobacter agglomerans* AJ13601 strain can grow not only at an acidic pH, but also at a neutral pH. Therefore, it was confirmed as follows that L-glutamic acid crystals could also be precipitated by starting the culture at a neutral pH and allowing production of L-glutamic acid during the culture so that pH of the culture should spontaneously be lowered.

Cells of one plate (8.5 cm in diameter) of the *Enterobacter agglomerans* AJ13601 strain, cultured on LBG agar medium (10 g/ of L tryptone, 5 g/L of yeast extract, 10 g/L of NaCl, 5 g/L of glucose, 15 g/L of agar) containing 25 mg/L of tetracycline hydrochloride and 25 mg/L of chloramphenicol at 30°C for 14 hours, were inoculated into a 1-L jar fermenter containing 300 ml of medium containing 40 g/L of glucose, 5 g/L of $(NH_4)_2SO_4$, 1.5 g/L of $MgSO_4 \cdot 7H_2O$, 6 g/L of KH_2PO_4, 1.5 g/L of NaCl, 0.75 g/L of $CaCl_2 \cdot 7H_2O$, 0.06 g/L of $FeSO_4 \cdot 7H_2O$, 0.06 g/L of $MnSO_4 \cdot 4H_2O$, 2.16 mg/L of $ZnSO_4 \cdot 2H_2O$, 1.92 mg/L of $CuSO_4 \cdot 5H_2O$, 2.16 mg/L of $CoCl_2 \cdot 6H_2O$, 1.2 mg/L of boric acid, 3.6 mg/L of $Na_2MoO_4 \cdot 2H_2O$, 6 g/L of yeast extract,

600 mg/L of L-lysine hydrochloride, 600 mg/L of L-methionine, 600 mg/L of DL-α,ε-diaminopimelic acid, 25 mg/L of tetracycline hydrochloride and 25 mg/L of chloramphenicol and the culture was started at 34°C and pH 7.0. The culture pH was controlled by introducing ammonia gas into the medium. As the initially added glucose was depleted, 600 g/L of glucose was continuously added.

As L-glutamic acid is accumulated, pH lowers spontaneously. The amount of the introduced ammonia gas was adjusted so that pH should be gradually lowered from 7.0 to 4.5 during the period between 15 hours and 24 hours after the start of the culture, and 24 hours after the start of the culture, pH became 4.5. Afterward, cultivation was continued for 12 hours.

As a result of the culture for L-glutamic acid production conducted for 36 hours as described above, a substantial amount of L-glutamic acid crystals were precipitated in the jar fermenter. Table 3 shows the concentration of L-glutamic acid dissolved in the culture broth, the amount of L-glutamic acid present as crystals at that time and the L-glutamic acid concentration measured by dissolving the crystals in 2 M KOH solution. L-Glutamic acid crystals were collected from the culture by decantation after the culture was left stood.

Table 3

Concentration of L-glutamic acid dissolved in culture broth	45 g/L
Amount of L-glutamic acid precipitated as crystals	31 g/L
Concentration of L-glutamic acid measured by dissolving crystals	76 g/L

SEQUENCE LISTING

<110> Hiroshi Izui
Mika Moriya
Seiko Hirano
Yoshihiko Hara
Hisao Ito
Kazuhiko Matsui

<120> Method for producing L-glutamic acid by fermentation accompanied by precipitation

<130>

<150> JP 11-234806
<151> 1999-08-20

<150> JP 2000-78771
<151> 2000-03-21

<160> 7

<170> PatentIn Ver. 2.0

<210> 1
<211> 4556
<212> DNA
<213> Enterobacter agglomerans

<220>
<221> CDS
<222> (2)..(121)

<220>
<221> CDS
<222> (322)..(3129)

<220>
<221> CDS
<222> (3145)..(4368)

<220>
<221> CDS
<222> (4437)..(4556)

<400> 1
t gca ttc agc gtt ttc cgc tgt cac agc atc atg aac tgt gta agt gtt 49
  Ala Phe Ser Val Phe Arg Cys His Ser Ile Met Asn Cys Val Ser Val
    1   5   10   15
tgt cct aaa ggg cta aac ccg acg cgc gct atc ggc cac att aag tcg 97
Cys Pro Lys Gly Leu Asn Pro Thr Arg Ala Ile Gly His Ile Lys Ser
            20   25   30
atg ctg ctg caa cgc agc gcg tagttatacc accgggaacc tcaggttccc   148
Met Leu Leu Gln Arg Ser Ala

```
        35
ggtattttac ggaagcctct gtaaacgcgg tcccaaccac gtttacaaag gttcccttac 208
gggccgggcg cgcgctgcgc acagtgctcg tatcgctgaa ctcactacgg caaaccgcga 268
aagcggcaac aaatgaaacc tcaaaaaagc ataacattgc ttaagggatc aca atg     324
                                                            Met
                                                             1
cag aac agc gcg atg aag ccc tgg ctg gac tcc tcc tgg ctg gcc ggc   372
Gln Asn Ser Ala Met Lys Pro Trp Leu Asp Ser Ser Trp Leu Ala Gly
             5                  10                  15
gcg aat cag tct tac ata gag caa ctc tat gag gat ttc ctg acc gat   420
Ala Asn Gln Ser Tyr Ile Glu Gln Leu Tyr Glu Asp Phe Leu Thr Asp
         20                  25                  30
cct gac tct gtg gat gca gtg tgg cgc tcg atg ttc caa cag tta cca   468
Pro Asp Ser Val Asp Ala Val Trp Arg Ser Met Phe Gln Gln Leu Pro
     35                  40                  45
ggc acg gga gtg aaa cct gag cag ttc cac tcc gca act cgc gaa tat   516
Gly Thr Gly Val Lys Pro Glu Gln Phe His Ser Ala Thr Arg Glu Tyr
 50                  55                  60                  65
ttc cgt cgc ctg gcg aaa gac gca tct cgt tac acc tcc tca gtt acc   564
Phe Arg Arg Leu Ala Lys Asp Ala Ser Arg Tyr Thr Ser Ser Val Thr
                 70                  75                  80
gat ccg gca acc aac tcc aaa caa gtg aaa gtg ctg cag ctg att aac   612
Asp Pro Ala Thr Asn Ser Lys Gln Val Lys Val Leu Gln Leu Ile Asn
             85                  90                  95
gcg ttt cgt ttc cgc gga cat cag gaa gca aat ctc gat ccg ctt ggc   660
Ala Phe Arg Phe Arg Gly His Gln Glu Ala Asn Leu Asp Pro Leu Gly
         100                 105                 110
ctg tgg aaa cag gac cgc gtt gcc gat ctc gat cct gcc ttt cac gat   708
Leu Trp Lys Gln Asp Arg Val Ala Asp Leu Asp Pro Ala Phe His Asp
     115                 120                 125
ctg acc gac gcc gat ttt cag gaa agc ttt aac gta ggt tct ttt gcc   756
Leu Thr Asp Ala Asp Phe Gln Glu Ser Phe Asn Val Gly Ser Phe Ala
130                 135                 140                 145
att ggc aaa gaa acc atg aag ctg gcc gat ctg ttc gac gcg ctg aag   804
Ile Gly Lys Glu Thr Met Lys Leu Ala Asp Leu Phe Asp Ala Leu Lys
                 150                 155                 160
cag acc tac tgt ggc tcg att ggt gca gag tat atg cac atc aat aac   852
Gln Thr Tyr Cys Gly Ser Ile Gly Ala Glu Tyr Met His Ile Asn Asn
             165                 170                 175
acc gaa gag aaa cgc tgg atc cag cag cgt atc gaa tcc ggt gcg agc   900
Thr Glu Glu Lys Arg Trp Ile Gln Gln Arg Ile Glu Ser Gly Ala Ser
         180                 185                 190
cag acg tca ttc agt ggc gaa gag aaa aaa ggt ttc ctg aaa gag ctg   948
Gln Thr Ser Phe Ser Gly Glu Glu Lys Lys Gly Phe Leu Lys Glu Leu
     195                 200                 205
acc gcg gca gaa ggg ctg gaa aaa tat ctg ggc gcg aaa ttc ccg ggt   996
Thr Ala Ala Glu Gly Leu Glu Lys Tyr Leu Gly Ala Lys Phe Pro Gly
210                 215                 220                 225
gca aaa cgt ttc tcg ctg gaa ggc ggt gat gcg ctg gtg ccg atg ctg   1044
Ala Lys Arg Phe Ser Leu Glu Gly Gly Asp Ala Leu Val Pro Met Leu
                 230                 235                 240
cgc gag atg att cgt cat gcg ggc aaa agc ggc aca cgt gaa gtg gta   1092
Arg Glu Met Ile Arg His Ala Gly Lys Ser Gly Thr Arg Glu Val Val
             245                 250                 255
```

```
ctg ggg atg gcg cac cgt ggc cgt ctt aac gta ctg att aac gta ctg   1140
Leu Gly Met Ala His Arg Gly Arg Leu Asn Val Leu Ile Asn Val Leu
        260                 265                 270
ggt aaa aag cca cag gat ctg ttc gac gaa ttc tcc ggt aaa cac aaa   1188
Gly Lys Lys Pro Gln Asp Leu Phe Asp Glu Phe Ser Gly Lys His Lys
    275                 280                 285
gag cat ctg ggc acc ggt gat gtg aag tat cac atg ggc ttc tct tcg   1236
Glu His Leu Gly Thr Gly Asp Val Lys Tyr His Met Gly Phe Ser Ser
290                 295                 300                 305
gat att gaa acc gaa ggt ggt ctg gtg cat ctg gcg ctg gcg ttt aac   1284
Asp Ile Glu Thr Glu Gly Gly Leu Val His Leu Ala Leu Ala Phe Asn
                310                 315                 320
ccg tct cac ctg gaa att gtc agc ccg gtg gtc atg gga tcg gta cgt   1332
Pro Ser His Leu Glu Ile Val Ser Pro Val Val Met Gly Ser Val Arg
            325                 330                 335
gca cgt ctc gat cgt ctg gcc gaa ccg gtc agc aat aaa gtg ttg cct   1380
Ala Arg Leu Asp Arg Leu Ala Glu Pro Val Ser Asn Lys Val Leu Pro
        340                 345                 350
atc acc att cac ggt gat gcg gcg gtg att ggt cag ggc gtg gtt cag   1428
Ile Thr Ile His Gly Asp Ala Ala Val Ile Gly Gln Gly Val Val Gln
    355                 360                 365
gaa acc ctg aac atg tct cag gcg cgc ggc tac gaa gtg ggc ggc acg   1476
Glu Thr Leu Asn Met Ser Gln Ala Arg Gly Tyr Glu Val Gly Gly Thr
370                 375                 380                 385
gta cgt atc gtc att aac aac cag gtt ggt ttt acc acc tcc aac ccg   1524
Val Arg Ile Val Ile Asn Asn Gln Val Gly Phe Thr Thr Ser Asn Pro
                390                 395                 400
aaa gat gcg cgt tca acc ccg tac tgt act gac atc ggc aag atg gtg   1572
Lys Asp Ala Arg Ser Thr Pro Tyr Cys Thr Asp Ile Gly Lys Met Val
            405                 410                 415
ctg gca ccg att ttc cac gtc aat gct gac gat ccg gaa gcg gtg gcc   1620
Leu Ala Pro Ile Phe His Val Asn Ala Asp Asp Pro Glu Ala Val Ala
        420                 425                 430
ttt gtt acc cgc ctg gcg ctg gac tat cgc aac acc ttc aaa cgc gat   1668
Phe Val Thr Arg Leu Ala Leu Asp Tyr Arg Asn Thr Phe Lys Arg Asp
    435                 440                 445
gtg ttt atc gat ctg gtg tgc tat cgc cgt cat ggt cac aac gag gcg   1716
Val Phe Ile Asp Leu Val Cys Tyr Arg Arg His Gly His Asn Glu Ala
450                 455                 460                 465
gat gag cca agt gct acc cag ccg ttg atg tac cag aaa atc aaa aag   1764
Asp Glu Pro Ser Ala Thr Gln Pro Leu Met Tyr Gln Lys Ile Lys Lys
                470                 475                 480
cat ccg acg ccg cgt aaa att tac gcc gat cgt ctg gaa ggc gaa ggt   1812
His Pro Thr Pro Arg Lys Ile Tyr Ala Asp Arg Leu Glu Gly Glu Gly
            485                 490                 495
gtc gcg tcg cag gaa gat gcc acc gag atg gtg aac ctg tac cgc gat   1860
Val Ala Ser Gln Glu Asp Ala Thr Glu Met Val Asn Leu Tyr Arg Asp
        500                 505                 510
gcg ctc gat gcg ggc gaa tgc gtg gtg ccg gaa tgg cgt ccg atg agc   1908
Ala Leu Asp Ala Gly Glu Cys Val Val Pro Glu Trp Arg Pro Met Ser
    515                 520                 525
ctg cac tcc ttc acg tgg tcg cct tat ctg aac cac gaa tgg gat gag   1956
Leu His Ser Phe Thr Trp Ser Pro Tyr Leu Asn His Glu Trp Asp Glu
530                 535                 540                 545
```

```
cct tat ccg gca cag gtt gac atg aaa cgc ctg aag gaa ctg gca ttg   2004
Pro Tyr Pro Ala Gln Val Asp Met Lys Arg Leu Lys Glu Leu Ala Leu
                550                 555                 560
cgt atc agc cag gtc cct gag cag att gaa gtg cag tcg cgc gtg gcc   2052
Arg Ile Ser Gln Val Pro Glu Gln Ile Glu Val Gln Ser Arg Val Ala
            565                 570                 575
aag atc tat aac gat cgc aag ctg atg gcc gaa ggc gag aaa gcg ttc   2100
Lys Ile Tyr Asn Asp Arg Lys Leu Met Ala Glu Gly Glu Lys Ala Phe
        580                 585                 590
gac tgg ggc ggt gcc gag aat ctg gcg tac gcc acg ctg gtg gat gaa   2148
Asp Trp Gly Gly Ala Glu Asn Leu Ala Tyr Ala Thr Leu Val Asp Glu
    595                 600                 605
ggt att ccg gtt cgc ctc tcg ggt gaa gac tcc ggt cgt gga acc ttc   2196
Gly Ile Pro Val Arg Leu Ser Gly Glu Asp Ser Gly Arg Gly Thr Phe
610                 615                 620                 625
ttc cat cgc cac gcg gtc gtg cac aac cag gct aac ggt tca acc tat   2244
Phe His Arg His Ala Val Val His Asn Gln Ala Asn Gly Ser Thr Tyr
                630                 635                 640
acg ccg ctg cac cat att cat aac agc cag ggc gag ttc aaa gtc tgg   2292
Thr Pro Leu His His Ile His Asn Ser Gln Gly Glu Phe Lys Val Trp
            645                 650                 655
gat tcg gtg ctg tct gaa gaa gcg gtg ctg gcg ttt gaa tac ggt tac   2340
Asp Ser Val Leu Ser Glu Glu Ala Val Leu Ala Phe Glu Tyr Gly Tyr
        660                 665                 670
gcc acg gct gag ccg cgc gtg ctg acc atc tgg gaa gcg cag ttt ggt   2388
Ala Thr Ala Glu Pro Arg Val Leu Thr Ile Trp Glu Ala Gln Phe Gly
    675                 680                 685
gac ttt gcc aac ggt gct cag gtg gtg att gac cag ttc atc agc tct   2436
Asp Phe Ala Asn Gly Ala Gln Val Val Ile Asp Gln Phe Ile Ser Ser
690                 695                 700                 705
ggc gaa cag aag tgg ggc cgt atg tgt ggc ctg gtg atg ttg ctg ccg   2484
Gly Glu Gln Lys Trp Gly Arg Met Cys Gly Leu Val Met Leu Leu Pro
                710                 715                 720
cat ggc tac gaa ggt cag gga ccg gaa cac tcc tct gcc cgt ctg gaa   2532
His Gly Tyr Glu Gly Gln Gly Pro Glu His Ser Ser Ala Arg Leu Glu
            725                 730                 735
cgc tat ctg caa ctt tgc gcc gag cag aac atg cag gtt tgc gtc ccg   2580
Arg Tyr Leu Gln Leu Cys Ala Glu Gln Asn Met Gln Val Cys Val Pro
        740                 745                 750
tcg acg ccg gct cag gtg tat cac atg ctg cgc cgt cag gcg ctg cgc   2628
Ser Thr Pro Ala Gln Val Tyr His Met Leu Arg Arg Gln Ala Leu Arg
    755                 760                 765
ggg atg cgc cgt ccg ctg gtg gtg atg tcg ccg aag tcg ctg tta cgc   2676
Gly Met Arg Arg Pro Leu Val Val Met Ser Pro Lys Ser Leu Leu Arg
770                 775                 780                 785
cat cca ctg gcg atc tcg tcg ctg gat gaa ctg gca aac ggc agt ttc   2724
His Pro Leu Ala Ile Ser Ser Leu Asp Glu Leu Ala Asn Gly Ser Phe
                790                 795                 800
cag ccg gcc att ggt gag atc gac gat ctg gat ccg cag ggc gtg aaa   2772
Gln Pro Ala Ile Gly Glu Ile Asp Asp Leu Asp Pro Gln Gly Val Lys
            805                 810                 815
cgc gtc gtg ctg tgc tcc ggt aag gtt tac tac gat ctg ctg gaa cag   2820
Arg Val Val Leu Cys Ser Gly Lys Val Tyr Tyr Asp Leu Leu Glu Gln
        820                 825                 830
```

```
cgt cgt aaa gac gag aaa acc gat gtt gcc atc gtg cgc atc gaa cag   2868
Arg Arg Lys Asp Glu Lys Thr Asp Val Ala Ile Val Arg Ile Glu Gln
    835                 840                 845
ctt tac ccg ttc ccg cat cag gcg gta cag gaa gca ttg aaa gcc tat   2916
Leu Tyr Pro Phe Pro His Gln Ala Val Gln Glu Ala Leu Lys Ala Tyr
850                 855                 860                 865
tct cac gta cag gac ttt gtc tgg tgc cag gaa gag cct ctg aac cag   2964
Ser His Val Gln Asp Phe Val Trp Cys Gln Glu Glu Pro Leu Asn Gln
                870                 875                 880
ggc gcc tgg tac tgt agc cag cat cat ttc cgt gat gtc gtg ccg ttt   3012
Gly Ala Trp Tyr Cys Ser Gln His His Phe Arg Asp Val Val Pro Phe
            885                 890                 895
ggt gcc acc ctg cgt tat gca ggt cgc ccg gca tcg gct tct ccg gcc   3060
Gly Ala Thr Leu Arg Tyr Ala Gly Arg Pro Ala Ser Ala Ser Pro Ala
        900                 905                 910
gtg ggt tat atg tcc gta cac caa caa cag cag caa gac ctg gtt aat   3108
Val Gly Tyr Met Ser Val His Gln Gln Gln Gln Gln Asp Leu Val Asn
    915                 920                 925
gac gca ctg aac gtc aat taattaaaag gaaagata atg agt agc gta gat   3159
Asp Ala Leu Asn Val Asn                     Met Ser Ser Val Asp
930                 935                       1               5
att ctc gtt ccc gac ctg cct gaa tcg gtt gca gat gcc aca gta gca   3207
Ile Leu Val Pro Asp Leu Pro Glu Ser Val Ala Asp Ala Thr Val Ala
                10                  15                  20
acc tgg cac aag aaa cca ggc gat gca gtc agc cgc gat gaa gtc atc   3255
Thr Trp His Lys Lys Pro Gly Asp Ala Val Ser Arg Asp Glu Val Ile
            25                  30                  35
gtc gaa att gaa act gac aaa gtc gtg ctg gaa gtg ccg gca tct gcc   3303
Val Glu Ile Glu Thr Asp Lys Val Val Leu Glu Val Pro Ala Ser Ala
        40                  45                  50
gat ggc gtg ctg gaa gcc gtg ctg gaa gac gaa ggg gca acc gtt acg   3351
Asp Gly Val Leu Glu Ala Val Leu Glu Asp Glu Gly Ala Thr Val Thr
    55                  60                  65
tcc cgc cag atc ctg ggt cgc ctg aaa gaa ggc aac agt gcg ggt aaa   3399
Ser Arg Gln Ile Leu Gly Arg Leu Lys Glu Gly Asn Ser Ala Gly Lys
70                  75                  80                  85
gaa agc agt gcc aaa gcg gaa agc aat gac acc acg cca gcc cag cgt   3447
Glu Ser Ser Ala Lys Ala Glu Ser Asn Asp Thr Thr Pro Ala Gln Arg
                90                  95                  100
cag aca gcg tcg ctt gaa gaa gag agc agc gat gcg ctc agc ccg gcg   3495
Gln Thr Ala Ser Leu Glu Glu Glu Ser Ser Asp Ala Leu Ser Pro Ala
            105                 110                 115
atc cgt cgc ctg att gcg gag cat aat ctt gac gct gcg cag atc aaa   3543
Ile Arg Arg Leu Ile Ala Glu His Asn Leu Asp Ala Ala Gln Ile Lys
        120                 125                 130
ggc acc ggc gta ggc gga cgt tta acg cgt gaa gac gtt gaa aaa cat   3591
Gly Thr Gly Val Gly Gly Arg Leu Thr Arg Glu Asp Val Glu Lys His
    135                 140                 145
ctg gcg aac aaa ccg cag gct gag aaa gcc gcc gcg cca gcg gcg ggt   3639
Leu Ala Asn Lys Pro Gln Ala Glu Lys Ala Ala Ala Pro Ala Ala Gly
150                 155                 160                 165
gca gca acg gct cag cag cct gtt gcc aac cgc agc gaa aaa cgt gtt   3687
Ala Ala Thr Ala Gln Gln Pro Val Ala Asn Arg Ser Glu Lys Arg Val
                170                 175                 180
```

```
ccg atg acg cgt tta cgt aag cgc gtc gcg gag cgt ctg ctg gaa gcc   3735
Pro Met Thr Arg Leu Arg Lys Arg Val Ala Glu Arg Leu Leu Glu Ala
            185                 190                 195
aag aac agc acc gcc atg ttg acg acc ttc aac gaa atc aac atg aag   3783
Lys Asn Ser Thr Ala Met Leu Thr Thr Phe Asn Glu Ile Asn Met Lys
        200                 205                 210
ccg att atg gat ctg cgt aag cag tac ggc gat gcg ttc gag aag cgt   3831
Pro Ile Met Asp Leu Arg Lys Gln Tyr Gly Asp Ala Phe Glu Lys Arg
    215                 220                 225
cac ggt gtg cgt ctg ggc ttt atg tct ttc tac atc aag gcc gtg gtc   3879
His Gly Val Arg Leu Gly Phe Met Ser Phe Tyr Ile Lys Ala Val Val
230                 235                 240                 245
gaa gcg ctg aag cgt tat cca gaa gtc aac gcc tct atc gat ggc gaa   3927
Glu Ala Leu Lys Arg Tyr Pro Glu Val Asn Ala Ser Ile Asp Gly Glu
                250                 255                 260
gac gtg gtg tac cac aac tat ttc gat gtg agt att gcc gtc tct acg   3975
Asp Val Val Tyr His Asn Tyr Phe Asp Val Ser Ile Ala Val Ser Thr
            265                 270                 275
cca cgc gga ctg gtg acg cct gtc ctg cgt gac gtt gat gcg ctg agc   4023
Pro Arg Gly Leu Val Thr Pro Val Leu Arg Asp Val Asp Ala Leu Ser
        280                 285                 290
atg gct gac atc gag aag aaa att aaa gaa ctg gca gtg aaa ggc cgt   4071
Met Ala Asp Ile Glu Lys Lys Ile Lys Glu Leu Ala Val Lys Gly Arg
    295                 300                 305
gac ggc aag ctg acg gtt gac gat ctg acg ggc ggt aac ttt acc atc   4119
Asp Gly Lys Leu Thr Val Asp Asp Leu Thr Gly Gly Asn Phe Thr Ile
310                 315                 320                 325
acc aac ggt ggt gtg ttc ggt tcg ctg atg tct acg cca atc atc aac   4167
Thr Asn Gly Gly Val Phe Gly Ser Leu Met Ser Thr Pro Ile Ile Asn
                330                 335                 340
ccg cca cag agc gcg att ctg ggc atg cac gcc att aaa gat cgt cct   4215
Pro Pro Gln Ser Ala Ile Leu Gly Met His Ala Ile Lys Asp Arg Pro
            345                 350                 355
atg gcg gtc aat ggt cag gtt gtg atc ctg cca atg atg tac ctg gct   4263
Met Ala Val Asn Gly Gln Val Val Ile Leu Pro Met Met Tyr Leu Ala
        360                 365                 370
ctc tcc tac gat cac cgt tta atc gat ggt cgt gaa tct gtc ggc tat   4311
Leu Ser Tyr Asp His Arg Leu Ile Asp Gly Arg Glu Ser Val Gly Tyr
    375                 380                 385
ctg gtc gcg gtg aaa gag atg ctg gaa gat ccg gcg cgt ctg ctg ctg   4359
Leu Val Ala Val Lys Glu Met Leu Glu Asp Pro Ala Arg Leu Leu Leu
390                 395                 400                 405
gat gtc tgattcatca ctgggcacgc gttgcgtgcc caatctcaat actcttttca   4415
Asp Val

gatctgaatg gatagaacat c atg aac tta cac gaa tac cag gct aaa cag   4466
                        Met Asn Leu His Glu Tyr Gln Ala Lys Gln
                          1               5                  10
ctg ttt gca cgg tat ggc atg cca gca ccg acc ggc tac gcc tgt act   4514
Leu Phe Ala Arg Tyr Gly Met Pro Ala Pro Thr Gly Tyr Ala Cys Thr
                    15                  20                  25
aca cca cgt gaa gca gaa gaa gcg gca tcg aaa atc ggt gca           4556
Thr Pro Arg Glu Ala Glu Glu Ala Ala Ser Lys Ile Gly Ala
                30                  35                  40
```

<210> 2
<211> 39
<212> PRT
<213> Enterobacter agglomerans

<400> 2
Ala Phe Ser Val Phe Arg Cys His Ser Ile Met Asn Cys Val Ser Val
1 5 10 15
Cys Pro Lys Gly Leu Asn Pro Thr Arg Ala Ile Gly His Ile Lys Ser
20 25 30
Met Leu Leu Gln Arg Ser Ala
35

<210> 3
<211> 935
<212> PRT
<213> Enterobacter agglomerans

<400> 3
Met Gln Asn Ser Ala Met Lys Pro Trp Leu Asp Ser Ser Trp Leu Ala
1 5 10 15
Gly Ala Asn Gln Ser Tyr Ile Glu Gln Leu Tyr Glu Asp Phe Leu Thr
20 25 30
Asp Pro Asp Ser Val Asp Ala Val Trp Arg Ser Met Phe Gln Gln Leu
35 40 45
Pro Gly Thr Gly Val Lys Pro Glu Gln Phe His Ser Ala Thr Arg Glu
50 55 60
Tyr Phe Arg Arg Leu Ala Lys Asp Ala Ser Arg Tyr Thr Ser Ser Val
65 70 75 80
Thr Asp Pro Ala Thr Asn Ser Lys Gln Val Lys Val Leu Gln Leu Ile
85 90 95
Asn Ala Phe Arg Phe Arg Gly His Gln Glu Ala Asn Leu Asp Pro Leu
100 105 110
Gly Leu Trp Lys Gln Asp Arg Val Ala Asp Leu Asp Pro Ala Phe His
115 120 125
Asp Leu Thr Asp Ala Asp Phe Gln Glu Ser Phe Asn Val Gly Ser Phe
130 135 140
Ala Ile Gly Lys Glu Thr Met Lys Leu Ala Asp Leu Phe Asp Ala Leu
145 150 155 160
Lys Gln Thr Tyr Cys Gly Ser Ile Gly Ala Glu Tyr Met His Ile Asn
165 170 175
Asn Thr Glu Glu Lys Arg Trp Ile Gln Gln Arg Ile Glu Ser Gly Ala
180 185 190
Ser Gln Thr Ser Phe Ser Gly Glu Glu Lys Lys Gly Phe Leu Lys Glu
195 200 205
Leu Thr Ala Ala Glu Gly Leu Glu Lys Tyr Leu Gly Ala Lys Phe Pro
210 215 220
Gly Ala Lys Arg Phe Ser Leu Glu Gly Gly Asp Ala Leu Val Pro Met
225 230 235 240
Leu Arg Glu Met Ile Arg His Ala Gly Lys Ser Gly Thr Arg Glu Val
245 250 255
Val Leu Gly Met Ala His Arg Gly Arg Leu Asn Val Leu Ile Asn Val
260 265 270

```
Leu Gly Lys Lys Pro Gln Asp Leu Phe Asp Glu Phe Ser Gly Lys His
        275                 280                 285
Lys Glu His Leu Gly Thr Gly Asp Val Lys Tyr His Met Gly Phe Ser
    290                 295                 300
Ser Asp Ile Glu Thr Glu Gly Gly Leu Val His Leu Ala Leu Ala Phe
305                 310                 315                 320
Asn Pro Ser His Leu Glu Ile Val Ser Pro Val Val Met Gly Ser Val
                325                 330                 335
Arg Ala Arg Leu Asp Arg Leu Ala Glu Pro Val Ser Asn Lys Val Leu
            340                 345                 350
Pro Ile Thr Ile His Gly Asp Ala Ala Val Ile Gly Gln Gly Val Val
        355                 360                 365
Gln Glu Thr Leu Asn Met Ser Gln Ala Arg Gly Tyr Glu Val Gly Gly
    370                 375                 380
Thr Val Arg Ile Val Ile Asn Asn Gln Val Gly Phe Thr Thr Ser Asn
385                 390                 395                 400
Pro Lys Asp Ala Arg Ser Thr Pro Tyr Cys Thr Asp Ile Gly Lys Met
                405                 410                 415
Val Leu Ala Pro Ile Phe His Val Asn Ala Asp Asp Pro Glu Ala Val
            420                 425                 430
Ala Phe Val Thr Arg Leu Ala Leu Asp Tyr Arg Asn Thr Phe Lys Arg
        435                 440                 445
Asp Val Phe Ile Asp Leu Val Cys Tyr Arg Arg His Gly His Asn Glu
    450                 455                 460
Ala Asp Glu Pro Ser Ala Thr Gln Pro Leu Met Tyr Gln Lys Ile Lys
465                 470                 475                 480
Lys His Pro Thr Pro Arg Lys Ile Tyr Ala Asp Arg Leu Glu Gly Glu
                485                 490                 495
Gly Val Ala Ser Gln Glu Asp Ala Thr Glu Met Val Asn Leu Tyr Arg
            500                 505                 510
Asp Ala Leu Asp Ala Gly Glu Cys Val Val Pro Glu Trp Arg Pro Met
        515                 520                 525
Ser Leu His Ser Phe Thr Trp Ser Pro Tyr Leu Asn His Glu Trp Asp
    530                 535                 540
Glu Pro Tyr Pro Ala Gln Val Asp Met Lys Arg Leu Lys Glu Leu Ala
545                 550                 555                 560
Leu Arg Ile Ser Gln Val Pro Glu Gln Ile Glu Val Gln Ser Arg Val
                565                 570                 575
Ala Lys Ile Tyr Asn Asp Arg Lys Leu Met Ala Glu Gly Glu Lys Ala
            580                 585                 590
Phe Asp Trp Gly Gly Ala Glu Asn Leu Ala Tyr Ala Thr Leu Val Asp
        595                 600                 605
Glu Gly Ile Pro Val Arg Leu Ser Gly Glu Asp Ser Gly Arg Gly Thr
    610                 615                 620
Phe Phe His Arg His Ala Val Val His Asn Gln Ala Asn Gly Ser Thr
625                 630                 635                 640
Tyr Thr Pro Leu His His Ile His Asn Ser Gln Gly Glu Phe Lys Val
                645                 650                 655
Trp Asp Ser Val Leu Ser Glu Glu Ala Val Leu Ala Phe Glu Tyr Gly
            660                 665                 670
Tyr Ala Thr Ala Glu Pro Arg Val Leu Thr Ile Trp Glu Ala Gln Phe
        675                 680                 685
Gly Asp Phe Ala Asn Gly Ala Gln Val Val Ile Asp Gln Phe Ile Ser
    690                 695                 700
```

```
Ser Gly Glu Gln Lys Trp Gly Arg Met Cys Gly Leu Val Met Leu Leu
705                 710                 715                 720
Pro His Gly Tyr Glu Gly Gln Gly Pro Glu His Ser Ser Ala Arg Leu
                725                 730                 735
Glu Arg Tyr Leu Gln Leu Cys Ala Glu Gln Asn Met Gln Val Cys Val
            740                 745                 750
Pro Ser Thr Pro Ala Gln Val Tyr His Met Leu Arg Arg Gln Ala Leu
        755                 760                 765
Arg Gly Met Arg Arg Pro Leu Val Val Met Ser Pro Lys Ser Leu Leu
    770                 775                 780
Arg His Pro Leu Ala Ile Ser Ser Leu Asp Glu Leu Ala Asn Gly Ser
785                 790                 795                 800
Phe Gln Pro Ala Ile Gly Glu Ile Asp Asp Leu Asp Pro Gln Gly Val
                805                 810                 815
Lys Arg Val Val Leu Cys Ser Gly Lys Val Tyr Tyr Asp Leu Leu Glu
            820                 825                 830
Gln Arg Arg Lys Asp Glu Lys Thr Asp Val Ala Ile Val Arg Ile Glu
        835                 840                 845
Gln Leu Tyr Pro Phe Pro His Gln Ala Val Gln Glu Ala Leu Lys Ala
    850                 855                 860
Tyr Ser His Val Gln Asp Phe Val Trp Cys Gln Glu Glu Pro Leu Asn
865                 870                 875                 880
Gln Gly Ala Trp Tyr Cys Ser Gln His His Phe Arg Asp Val Val Pro
                885                 890                 895
Phe Gly Ala Thr Leu Arg Tyr Ala Gly Arg Pro Ala Ser Ala Ser Pro
            900                 905                 910
Ala Val Gly Tyr Met Ser Val His Gln Gln Gln Gln Gln Asp Leu Val
        915                 920                 925
Asn Asp Ala Leu Asn Val Asn
    930                 935
```

<210> 4
<211> 407
<212> PRT
<213> Enterobacter agglomerans

<400> 4

```
Met Ser Ser Val Asp Ile Leu Val Pro Asp Leu Pro Glu Ser Val Ala
  1                 5                  10                  15
Asp Ala Thr Val Ala Thr Trp His Lys Lys Pro Gly Asp Ala Val Ser
             20                  25                  30
Arg Asp Glu Val Ile Val Glu Ile Glu Thr Asp Lys Val Val Leu Glu
         35                  40                  45
Val Pro Ala Ser Ala Asp Gly Val Leu Glu Ala Val Leu Glu Asp Glu
     50                  55                  60
Gly Ala Thr Val Thr Ser Arg Gln Ile Leu Gly Arg Leu Lys Glu Gly
 65                  70                  75                  80
Asn Ser Ala Gly Lys Glu Ser Ser Ala Lys Ala Glu Ser Asn Asp Thr
                 85                  90                  95
Thr Pro Ala Gln Arg Gln Thr Ala Ser Leu Glu Glu Glu Ser Ser Asp
            100                 105                 110
Ala Leu Ser Pro Ala Ile Arg Arg Leu Ile Ala Glu His Asn Leu Asp
        115                 120                 125
Ala Ala Gln Ile Lys Gly Thr Gly Val Gly Gly Arg Leu Thr Arg Glu
```

```
    130                 135                 140
Asp Val Glu Lys His Leu Ala Asn Lys Pro Gln Ala Glu Lys Ala Ala
145                 150                 155                 160
Ala Pro Ala Ala Gly Ala Ala Thr Ala Gln Gln Pro Val Ala Asn Arg
                165                 170                 175
Ser Glu Lys Arg Val Pro Met Thr Arg Leu Arg Lys Arg Val Ala Glu
            180                 185                 190
Arg Leu Leu Glu Ala Lys Asn Ser Thr Ala Met Leu Thr Thr Phe Asn
        195                 200                 205
Glu Ile Asn Met Lys Pro Ile Met Asp Leu Arg Lys Gln Tyr Gly Asp
    210                 215                 220
Ala Phe Glu Lys Arg His Gly Val Arg Leu Gly Phe Met Ser Phe Tyr
225                 230                 235                 240
Ile Lys Ala Val Val Glu Ala Leu Lys Arg Tyr Pro Glu Val Asn Ala
                245                 250                 255
Ser Ile Asp Gly Glu Asp Val Val Tyr His Asn Tyr Phe Asp Val Ser
            260                 265                 270
Ile Ala Val Ser Thr Pro Arg Gly Leu Val Thr Pro Val Leu Arg Asp
        275                 280                 285
Val Asp Ala Leu Ser Met Ala Asp Ile Glu Lys Lys Ile Lys Glu Leu
    290                 295                 300
Ala Val Lys Gly Arg Asp Gly Lys Leu Thr Val Asp Asp Leu Thr Gly
305                 310                 315                 320
Gly Asn Phe Thr Ile Thr Asn Gly Gly Val Phe Gly Ser Leu Met Ser
                325                 330                 335
Thr Pro Ile Ile Asn Pro Pro Gln Ser Ala Ile Leu Gly Met His Ala
            340                 345                 350
Ile Lys Asp Arg Pro Met Ala Val Asn Gly Gln Val Val Ile Leu Pro
        355                 360                 365
Met Met Tyr Leu Ala Leu Ser Tyr Asp His Arg Leu Ile Asp Gly Arg
    370                 375                 380
Glu Ser Val Gly Tyr Leu Val Ala Val Lys Glu Met Leu Glu Asp Pro
385                 390                 395                 400
Ala Arg Leu Leu Leu Asp Val
                405
```

<210> 5
<211> 40
<212> PRT
<213> Enterobacter agglomerans

<400> 5

```
Met Asn Leu His Glu Tyr Gln Ala Lys Gln Leu Phe Ala Arg Tyr Gly
  1               5                  10                  15
Met Pro Ala Pro Thr Gly Tyr Ala Cys Thr Thr Pro Arg Glu Ala Glu
             20                  25                  30
Glu Ala Ala Ser Lys Ile Gly Ala
         35                  40
```

<210> 6
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 6
gtcgacaata gccygaatct gttctggtcg 30

<210> 7
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 7
aagcttatcg acgctcccct ccccaccgtt 30

WHAT IS CLAIMED IS:

1. A microorganism which can metabolize a carbon source at a specific pH in a liquid medium containing L-glutamic acid at a saturation concentration and the carbon source, and has ability to accumulate L-glutamic acid in an amount exceeding the amount corresponding to the saturation concentration in the liquid medium at the pH.

2. The microorganism according to claim 1, which can grow in the liquid medium.

3. The microorganism according to claim 1 or 2, wherein the pH is not more than 5.0.

4. The microorganism according to any one of claims 1-3, which has at least one of the following characteristics:

(a) the microorganism is enhanced in activity of an enzyme that catalyzes a reaction for biosynthesis of L-glutamic acid; and

(b) the microorganism is decreased in or deficient in activity of an enzyme that catalyzes a reaction branching from a biosynthetic pathway of L-glutamic acid and producing a compound other than L-glutamic acid by.

5. The microorganism according to claim 4, wherein the enzyme that catalyzes the reaction for biosynthesis of L-glutamic acid is at least one selected from citrate synthase, phosphoenolpyruvate carboxylase and glutamate dehydrogenase.

6. The microorganism according to claim 4 or 5, wherein the enzyme that catalyzes the reaction branching from the biosynthetic pathway of L-glutamic acid and producing

the compound other than L-glutamic acid is α-ketoglutarate dehydrogenase.

7. The microorganism according to any one of claims 1-6, wherein the microorganism belongs to the genus *Enterobacter*.

8. The microorganism according to claim 7, which is *Enterobacter agglomerans*.

9. The microorganism according to claim 8, which has a mutation that causes less extracellular secretion of a viscous material compared with a wild strain when cultured in a medium containing a saccharide.

10. A method for producing L-glutamic acid by fermentation, which comprises culturing a microorganism as defined in any one of claim 1-9 in a liquid medium of which pH is adjusted to a pH at which L-glutamic acid is precipitated, to produce and accumulate L-glutamic acid and precipitate L-glutamic acid in the medium.

11. A method for screening a microorganism suitable for producing L-glutamic acid by fermentation with precipitating L-glutamic acid in a liquid medium, which comprises inoculating a sample containing microorganisms into an acidic medium containing L-glutamic acid at a saturation concentration and a carbon source, and selecting a strain that can metabolize the carbon source.

12. The method according to claim 11, wherein a strain that can grow in the medium is selected as the strain that can metabolize the carbon source.

13. The method according to claim 11 or 12, wherein

a pH of the medium is not more than 5.0.

ABSTRACT OF THE DISCLOSURE

A microorganism which can metabolize a carbon source at a specific pH in a liquid medium containing L-glutamic acid at a saturation concentration and the carbon source, and has ability to accumulate L-glutamic acid in an amount exceeding the amount corresponding to the saturation concentration in the liquid medium at the pH; and a method for producing L-glutamic acid by fermentation, which comprises culturing the microorganism in a liquid medium of which pH is adjusted to a pH at which L-glutamic acid is precipitated, to produce and accumulate L-glutamic acid and precipitate L-glutamic acid in the medium.


(EcoT22I/PstI)
HindIII
BamHI
BglII
BamHI
SphI
BglII
(EcoT22I/PstI)
pTWVEK101
PstI
EcoRI
SalI
SmaI
SphI
1 kb
sdhB
sucA
sucB
sucC
Derived from Entrobacter agglomerans
Derived from pTWV228

Fig. 1

[88.0% / 935 aa]

```
   1' MQNSAMKPWLDSSWLAGANQSYIEQLYEDFLTDPDSVDAVWRSMFQQLPGTGVKPEQFHS
      ***** * ***** * ***** ***************** *** ********** ****
   1" MQNSALKAWLDSSYLSGANQSWIEQLYEDFLTDPDSVDANWRSTFQQLPGTGVKPDQFHS

  61' ATREYFRRLAKDASRYTSSVTDPATNSKQVKVLQLINAFRFRGHQEANLDPLGLWKQDRV
      ***************.*...**.** ********** ****** ********* **.*
  61" QTREYFRRLAKDASRYSSTISDPDTNVKQVKVLQLINAYRFRGHQHANLDPLGLWQQDKV

 121' ADLDPAFHDLTDADFQESFNVGSFAIGKETMKLADLFDALKQTYCGSIGAEYMHINNTEE
      ***** ***** ***** ******* ******* .*. ******** ******** .***
 121" ADLDPSFHDLTEADFQETFNVGSFASGKETMKLGELLEALKQTYCGPIGAEYMHITSTEE

 181' KRWIQQRIESGASQTSFSGEEKKGFLKELTAAEGLEKYLGAKFPGAKRFSLEGGDALVPM
      ********** ...*..**** ** .*********.******************.**
 181" KRWIQQRIESG--RATFNSEEKKRFLSELTAAEGLERYLGAKFPGAKRFSLEGGDALIPM

 241' LREMIRHAGKSGTREVVLGMAHRGRLNVLINVLGKKPQDLFDEFSGKHKEHLGTGDVKYH
      *.******* ********************.*************.**************
 239" LKEMIRHAGNSGTREVVLGMAHRGRLNVLVNVLGKKPQDLFDEFAGKHKEHLGTGDVKYH

 301' MGFSSDIETEGGLVHLALAFNPSHLEIVSPVVMGSVRARLDRLAEPVSNKVLPITIHGDA
      ****** ..*.********************.********** ** ************
 299" MGFSSDFQTDGGLVHLALAFNPSHLEIVSPVVIGSVRARLDRLDEPSSNKVLPITIHGDA

 361' AVIGQGVVQETLNMSQARGYEVGGTVRIVINNQVGFTTSNPKDARSTPYCTDIGKMVLAP
      **.************************************ ************** **
 359" AVTGQGVVQETLNMSKARGYEVGGTVRIVINNQVGFTTSNPLDARSTPYCTDIGKMVQAP

 421' IFHVNADDPEAVAFVTRLALDYRNTFKRDVFIDLVCYRRHGHNEADEPSATQPLMYQKIK
      ********************.*************.************************
 419" IFHVNADDPEAVAFVTRLALDFRNTFKRDVFIDLVSYRRHGHNEADEPSATQPLMYQKIK

 481' KHPTPRKIYADRLEGEGVASQEDATEMVNLYRDALDAGECVVPEWRPMSLHSFTWSPYLN
      ***********.** * **. ****************.***.******..**********
 479" KHPTPRKIYADKLEQEKVATLEDATEMVNLYRDALDAGDCVVAEWRPMNMHSFTWSPYLN

 541' HEWDEPYPAQVDMKRLKELALRISQVPEQIEVQSRVAKIYNDRKLMAEGEKAFDWGGAEN
      ***** ** ..*.****.*** *** ***..*.********.**. **.*** ********
 539" HEWDEEYPNKVEMKRLQELAKRISTVPEAVEMQSRVAKIYGDRQAMAAGEKLFDWGGAEN

 601' LAYATLVDEGIPVRLSGEDSGRGTFFHRHAVVHNQANGSTYTPLHHIHNSQGEFKVWDSV
      ****************************.***.********.****.**.*.******
 599" LAYATLVDEGIPVRLSGEDSGRGTFFHRHAVIHNQSNGSTYTPLQHIHNGQGAFRVWDSV

 661' LSEEAVLAFEYGYATAEPRVLTIWEAQFGDFANGAQVVIDQFISSGEQKWGRMCGLVMLL
      ******************.**************************************
 659" LSEEAVLAFEYGYATAEPRTLTIWEAQFGDFANGAQVVIDQFISSGEQKWGRMCGLVMLL

 721' PHGYEGQGPEHSSARLERYLQLCAEQNMQVCVPSTPAQVYHMLRRQALRGMRRPLVVMSP
      ************************************************************
 719" PHGYEGQGPEHSSARLERYLQLCAEQNMQVCVPSTPAQVYHMLRRQALRGMRRPLVVMSP

 781' KSLLRHPLAISSLDELANGSFQPAIGEIDDLDPQGVKRVVLCSGKVYYDLLEQRRKDEKT
      *********.***.*****.* *******.***.*********.************...
 779" KSLLRHPLAVSSLEELANGTFLPAIGEIDELDPKGVKRVVMCSGKVYYDLLEQRRKNNQH

 841' DVAIVRIEQLYPFPHQAVQEALKAYSHVQDFVWCQEEPLNQGAWYCSQHHFRDVVPFGAT
      ***************.*.**.*....**.*********************.*.*****.
 839" DVAIVRIEQLYPFPHKAMQEVLQQFAHVKDFVWCQEEPLNQGAWYCSQHHFREVIPFGAS

 901' LRYAGRPASASPAVGYMSVHQQQQQDLVNDALNVN
      **********************.************.
 899" LRYAGRPASASPAVGYMSVHQKQQQDLVNDALNVE
```

Fig. 2

```
[88.2% / 407 aa]

     1' MSSVDILVPDLPESVADATVATWHKKPGDAVSRDEVIVEIETDKVVLEVPASADGVLEAV
        ********************************* **** ********************.* **
     1" MSSVDILVPDLPESVADATVATWHKKPGDAVVRDEVLVEIETDKVVLEVPASADGILDAV

    61' LEDEGATVTSRQILGRLKEGNSAGKESSAKAESNDTTPAQRQTASLEEESSDALSPAIRR
        ****** ********** ******** *** * .... ****** ****** ... **********
    61" LEDEGTTVTSRQILGRLREGNSAGKETSAKSEEKASTPAQRQQASLEEQNNDALSPAIRR

   121' LIAEHNLDAAQIKGTGVGGRLTREDVEKHLANKPQAEKAAAPAAGAATAQQPVANRSEKR
        * ******* ********************* * * . **** * .. ** . * ******
   121" LLAEHNLDASAIKGTGVGGRLTREDVEKHLAKAPAKE--SAPAAAAPAAQPALAARSEKR

   181' VPMTRLRKRVAERLLEAKNSTAMLTTFNEINMKPIMDLRKQYGDAFEKRHGVRLGFMSFY
        ************************* ********** ******* ********
   179" VPMTRLRKRVAERLLEAKNSTAMLTTFNEVNMKPIMDLRKQYGEAFEKRHGIRLGFMSFY

   241' IKAVVEALKRYPEVNASIDGEDVVYHNYFDVSIAVSTPRGLVTPVLRDVDALSMADIEKK
        ********************* ********** ********** ********
   239" VKAVVEALKRYPEVNASIDGDDVVYHNYFDVSMAVSTPRGLVTPVLRDVDTLGMADIEKK

   301' IKELAVKGRDGKLTVDDLTGGNFTITNGGVFGSLMSTPIINPPQSAILGMHAIKDRPMAV
        ************** ************************************************
   299" IKELAVKGRDGKLTVEDLTGGNFTITNGGVFGSLMSTPIINPPQSAILGMHAIKDRPMAV

   361' NGQVVILPMMYLALSYDHRLIDGRESVGYLVAVKEMLEDPARLLLDV
        **** ********************* ** ** **** ******
   359" NGQVEILPMMYLALSYDHRLIDGRESVGFLVTIKELLEDPTRLLLDV
```

Fig. 3

```
[95.1% / 41 aa]

     1' MNLHEYQAKQLFARYGMPAPTGYACTTPREAEEAASKIGAG
        ***************** *** ********************
     1" MNLHEYQAKQLFARYGLPAPVGYACTTPREAEEAASKIGAGPWVVKCQVHAGGRGKAGGV
```

Fig. 4

```
[97.4% / 39 aa]

     1'                          AFSVFRCHSIMNCVSVCPKGLNPTRAIGHIKSMLLQRSA
                                 ****************************************.*
   181" FLIDSRDTETDSRLDGLSDAFSVFRCHSIMNCVSVCPKGLNPTRAIGHIKSMLLQRNA
```

Fig. 5



S;SalI
E;EcoRI
Sp;SphI
X;XbaI
H;HindIII

Fig. 6


N
Sm
pVIC40
thr operon
P
NotI digestion
T4 DNA polymerase
PstI digestion
E
P
Amp
Tet
pBR322
E14
EcoT14I digestion
T4 DNA polymerase
PstI digestion
Ligation
E
P
Tet
RSF-Tet
E;EcoRI
E14;EcoT14I
P;PstI
N;NotI

Fig. 7



E;EcoRI
P;PstI

Fig. 8


glt A
pHSG399
SmaI digestion
Ligation
pHSGCB
lacp
Hin d III
Hin d III
glt A
HindIII digestion
pSTV29
HindIII digestion
Ligation
pSTVCB
lacp
Hin d III
Hin d III
glt A

Fig. 9

Declaration, Power Of Attorney and Petition

WE (I) the undersigned inventor(s), hereby declare(s) that:

My residence, post office address and citizenship are as stated below next to my name,

We (I) believe that we are (I am) the original, first, and joint (sole) inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled

METHOD FOR PRODUCING L-GLUTAMIC ACID BY FERMENTATION ACCOMPANIED BY PRECIPITATION

the specification of which

☒ is attached hereto.

☐ was filed on _____ as

Application Serial No. _____

and amended on _____.

☐ was filed as PCT international application

Number _____

on _____,

and was amended under PCT Article 19

on _____ (if applicable).

We (I) hereby state that we (I) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We (I) acknowledge the duty to disclose information known to be material to the patentability of this application as defined in Section 1.56 of Title 37 Code of Federal Regulations.

We (I) hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed. Prior Foreign Application(s)

Application No.	Country	Day/Month/Year	Priority Claimed	
11-234806	Japan	20/08/1999	☒ Yes	☐ No
2000-78771	Japan	21/03/2000	☒ Yes	☐ No
			☐ Yes	☐ No
			☐ Yes	☐ No

We (I) hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

(Application Number)	(Filing Date)
(Application Number)	(Filing Date)

We (I) hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.	Filing Date	Status (pending, patented, abandoned)

And we (I) hereby appoint: Norman F. Oblon, Registration Number 24,618; Marvin J. Spivak, Registration Number 24,913; C. Irvin McClelland, Registration Number 21,124; Gregory J. Maier, Registration Number 25,599; Arthur I. Neustadt, Registration Number 24,854; Richard D. Kelly, Registration Number 27,757; James D. Hamilton, Registration Number 28,421; Eckhard H. Kuesters, Registration Number 28,870; Robert T. Pous, Registration Number 29,099; Charles L. Gholz, Registration Number 26,395; Vincent J. Sunderdick, Registration Number 29,004; William E. Beaumont, Registration Number 30,996; Steven B. Kelber, Registration Number 30,073; Robert F. Gnuse, Registration Number 27,295; Jean-Paul Lavalleye, Registration Number 31,451; Timothy R. Schwartz, Registration Number 32,171; Stephen G. Baxter, Registration Number 32,884; Martin M. Zoltick, Registration Number 35,745; Robert W. Hahl, Registration Number 33,893; Richard L. Treanor, Registration Number 36,379; Steven P. Weihrouch, Registration Number 32,829; John T. Goolkasian, Registration Number 26,142; Marc R. Labgold, Registration Number 34,651; William J. Healey, Registration Number 36,160; and Richard L. Chinn, Registration Number 34,305; our (my) attorneys, with full powers of substitution and revocation, to prosecute this application and to transact all business in the Patent Office connected therewith; and we (I) hereby request that all correspondence regarding this application be sent to the firm of OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C., whose Post Office Address is: Fourth Floor, 1755 Jefferson Davis Highway, Arlington, Virginia 22202.

We (I) declare that all statements made herein of our (my) own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Hiroshi IZUI

NAME OF FIRST SOLE INVENTOR

Residence: Kawasaki-shi, Kanagawa, Japan



Signature of Inventor

Citizen of: Japan

Post Office Address: c/o Ajinomoto Co., Inc. Fermentation & Biotechnology Laboratories, 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan

August 2, 2000

Date

Mika MORIYA
NAME OF SECOND JOINT INVENTOR

Residence: Kawasaki-shi, Kanagawa, Japan

Signature of Inventor

Citizen of: Japan
Post Office Address: c/o Ajinomoto Co., Inc., Fermentation & Biotechnology Laboratories, 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan

August 2, 2000
Date

Seiko HIRANO
NAME OF THIRD JOINT INVENTOR

Residence: Kawasaki-shi, Kanagawa, Japan

Signature of Inventor

Citizen of: Japan
Post Office Address: c/o Ajinomoto Co., Inc., Fermentation & Biotechnology Laboratories, 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan

August 2, 2000
Date

Yoshihiko HARA
NAME OF FOURTH JOINT INVENTOR

Residence: Kawasaki-shi, Kanagawa, Japan

Signature of Inventor

Citizen of: Japan
Post Office Address: c/o Ajinomoto Co., Inc., Fermentation & Biotechnology Laboratories, 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan

August 2, 2000
Date

Hisao ITO
NAME OF FIFTH JOINT INVENTOR

Residence: Kawasaki-shi, Kanagawa, Japan

Signature of Inventor

Citizen of: Japan
Post Office Address: c/o Ajinomoto Co., Inc., Fermentation & Biotechnology Laboratories, 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan

August 2, 2000
Date

Kazuhiko MATSUI

NAME OF SIXTH JOINT INVENTOR

Residence: Kawasaki-shi, Kanagawa, Japan

Kazuhiko Matsui

Signature of Inventor

Citizen of: Japan

Post Office Address: c/o Ajinomoto Co., Inc., Fermentation & Biotechnology Laboratories, 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan

August 2, 2000

Date

NAME OF SEVENTH JOINT INVENTOR

Signature of Inventor

Date

NAME OF EIGHTH JOINT INVENTOR

Signature of Inventor

Date

NAME OF NINTH JOINT INVENTOR

Signature of Inventor

Date